U.S. patent application number 15/519543 was filed with the patent office on 2018-01-25 for novel methods, compounds, and compositions for anesthesia.
The applicant listed for this patent is THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS. Invention is credited to Edward John BERTACCINI, Margaret Frances DAVIES.
Application Number | 20180022698 15/519543 |
Document ID | / |
Family ID | 55747455 |
Filed Date | 2018-01-25 |
United States Patent
Application |
20180022698 |
Kind Code |
A1 |
BERTACCINI; Edward John ; et
al. |
January 25, 2018 |
NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR ANESTHESIA
Abstract
Methods of treatment useful in the inducement or maintenance of
anesthesia in a subject are provided. The methods comprise
administering to a subject in need of anesthesia a compound
disclosed herein. Also provided are novel compounds having
anesthetic effects, pharmaceutical compositions comprising the
compounds, and packaged pharmaceuticals. Computer modeling of the
compounds demonstrates favorable interactions with the GABA
receptor type A. In addition, the compounds display reversible
anesthetic effects in an animal model, with dose-response curves
similar to those of known general anesthetics. GABA
receptor-mediated effects are also demonstrated in a hippocampal
brain slice preparation.
Inventors: |
BERTACCINI; Edward John;
(San Jose, CA) ; DAVIES; Margaret Frances; (Palo
Alto, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF
VETERANS AFFAIRS |
Palo Alto
Washington |
CA
DC |
US
US |
|
|
Family ID: |
55747455 |
Appl. No.: |
15/519543 |
Filed: |
October 16, 2015 |
PCT Filed: |
October 16, 2015 |
PCT NO: |
PCT/US15/56067 |
371 Date: |
April 15, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62064670 |
Oct 16, 2014 |
|
|
|
Current U.S.
Class: |
549/486 |
Current CPC
Class: |
A61K 31/402 20130101;
C07D 207/34 20130101; A61P 25/22 20180101; A61K 31/40 20130101;
A61P 25/20 20180101; A61P 23/00 20180101 |
International
Class: |
C07D 207/34 20060101
C07D207/34 |
Claims
1-30. (canceled)
31. A compound represented by structural formula (II): ##STR00032##
or a pharmaceutically acceptable salt thereof, wherein: R.sub.p1
and R.sub.p2 are independently H, alkyl, alkenyl, alkynyl, alkoxy,
alkanoyl, alkylamino, cycloalkyl, cycloalkenyl, cycloalkoxy,
cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy,
heterocyclylamino, heterocyclylalky, heterocyclylalkoxy,
heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino,
alkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido, each
of which may be optionally substituted where chemically feasible;
R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group; R.sub.i2 is a
phenyl group optionally substituted with one or more alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido groups, and wherein two adjacent substituent
groups can combine to form a ring; R.sub.i3 is H or an
unsubstituted lower alkyl group; and R.sub.e is
C.sub.3-C.sub.8-alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl,
heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl, or
heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
provided that when R.sub.i1 is methyl, R.sub.i2 is unsubstituted
phenyl, and R.sub.e is benzyl, isopropyl, isobutyl, t-butyl,
methoxyethyl, or 4,4-difluoro-3-methyl-3-buten-1-yl, and R.sub.p1
is H, then R.sub.p2 is not H; when R.sub.i1 is methyl, R.sub.i2 is
2-methoxyphenyl, R.sub.e is t-butyl, and R.sub.p1 is H, then
R.sub.p2 is not H, 3-amino, 3-azido, 4-bromo, or 4-nitro; and when
R.sub.i1 is methyl, R.sub.i2 is 2-methoxyphenyl, R.sub.e is benzyl,
and R.sub.p1 is H, then R.sub.p2 is not H.
32. The compound of claim 31, wherein R.sub.i2 is a phenyl group
optionally substituted with one or more alkyl, alkoxy, hydroxyl,
thio, amino, carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido groups.
33. The compound of claim 32, wherein R.sub.i2 is a phenyl group
optionally substituted with one or more alkyl, alkoxy, or halo
groups.
34. The compound of claim 31, wherein R.sub.e is an optionally
substituted C.sub.3-C.sub.8-alkyl or aralkyl group.
35. The compound of claim 34, wherein R.sub.e is an optionally
substituted C.sub.3-C.sub.8-alkyl group.
36. The compound of claim 31, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, hydroxyl, thio, amino, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido.
37. The compound of claim 36, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, or halo.
38. A compound represented by structural formula (II): ##STR00033##
or a pharmaceutically acceptable salt thereof, wherein: R.sub.p1
and R.sub.p2 are independently H, alkyl, alkenyl, alkynyl, alkoxy,
alkanoyl, alkylamino, cycloalkyl, cycloalkenyl, cycloalkoxy,
cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy,
heterocyclylamino, heterocyclylalky, heterocyclylalkoxy,
heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino,
alkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido, each
of which may be optionally substituted where chemically feasible;
R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group; R.sub.i2 is a
phenyl group substituted with one or more alkyl, alkenyl, alkynyl,
alkoxy, alkanoyl, alkylamino, alkylthio, aryl, aryloxy, arylamino,
aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl,
heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy,
heteroaralkanoyl, heteroaralkamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido groups, and wherein two adjacent substituent
groups can combine to form a ring; R.sub.i3 is H or an
unsubstituted lower alkyl group; and R.sub.e is alkyl, alkenyl,
alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, or heterocyclylalky, and is optionally
substituted with alkyl, alkenyl, alkynyl, alkoxy, alkanoyl,
alkylamino, alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy,
aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido; provided that R.sub.i2 is not 2-aminophenyl, 3-aminophenyl,
3-amino-4-hydroxyphenyl, 4-aminophenyl, 3-azidophenyl,
1,1'-biphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-carboxyphenyl, 2-(chlorocarbonyl)phenyl, 4-chlorophenyl,
2,4-dichlorophenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl,
3,4-dimethylphenyl, 4-fluorophenyl, 2-methoxyphenyl,
3-methoxyphenyl, 4-methoxyphenyl, 3-(ethoxycarbonyl)phenyl,
4-(methoxycarbonyl)phenyl, 2-methylphenyl, 4-methylphenyl,
4-(methylsulfonyl)phenyl, 4-(methylthio)phenyl,
3-(4-morpholinylsulfonyl)phenyl, 2-nitrophenyl, 3-nitrophenyl,
4-nitrophenyl, 3-(phenylamino)phenyl, 4-(1H-pyrrol-1-yl)phenyl,
4-(1-methyl-1H-pyrazol-4-yl)phenyl, 2-hydroxy-5-aminophenyl, or
4-[5-(4-chlorophenyl)-3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]phenyl].
39. The compound of claim 38, wherein R.sub.i2 is a phenyl group
substituted with one or more alkyl, alkoxy, hydroxyl, thio, amino,
carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido groups.
40. The compound of claim 39, wherein R.sub.i2 is a phenyl group
substituted with one or more alkyl, alkoxy, or halo groups.
41. The compound of claim 38, wherein R.sub.e is an optionally
substituted lower alkyl or aralkyl group.
42. The compound of claim 41, wherein R.sub.e is an optionally
substituted lower alkyl group.
43. The compound of claim 38, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, hydroxyl, thio, amino, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido.
44. The compound of claim 43, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, or halo.
45-50. (canceled)
51. A compound represented by structural formula (II): ##STR00034##
or a pharmaceutically acceptable salt thereof, wherein: R.sub.p1
and R.sub.p2 are independently H, alkyl, alkenyl, alkynyl, alkoxy,
alkanoyl, alkylamino, cycloalkyl, cycloalkenyl, cycloalkoxy,
cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy,
heterocyclylamino, heterocyclylalky, heterocyclylalkoxy,
heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino,
alkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido, each
of which may be optionally substituted where chemically feasible;
R.sub.i1 is H; R.sub.i2 is a phenyl group optionally substituted
with one or more alkyl, alkenyl, alkynyl, alkoxy, alkanoyl,
alkylamino, alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy,
aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring; R.sub.i3 is H or an
unsubstituted lower alkyl group; and R.sub.e is alkyl, alkenyl,
alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, or heterocyclylalky, and is optionally
substituted with alkyl, alkenyl, alkynyl, alkoxy, alkanoyl,
alkylamino, alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy,
aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido; provided that when R.sub.i2 is 4-(methylsulfonyl)phenyl,
R.sub.e is methyl, and R.sub.p1 is H, then R.sub.p2 is not
4-fluoro; and when R.sub.i2 is unsubstituted phenyl, R.sub.e is
methyl, and R.sub.p1 is H, then R.sub.p2 is not 4-methoxy.
52. The compound of claim 51, wherein R.sub.i2 is a phenyl group
optionally substituted with one or more alkyl, alkoxy, hydroxyl,
thio, amino, carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido groups.
53. The compound of claim 52, wherein R.sub.i2 is a phenyl group
optionally substituted with one or more alkyl, alkoxy, or halo
groups.
54. The compound of claim 51, wherein R.sub.e is an optionally
substituted lower alkyl or aralkyl group.
55. The compound of claim 54, wherein R.sub.e is an optionally
substituted lower alkyl group.
56. The compound of claim 51, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, hydroxyl, thio, amino, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido.
57. The compound of claim 56, wherein R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, or halo.
58-59. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional
Application No. 62/064,670, filed on Oct. 16, 2014, the disclosure
of which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] For over 160 years, anesthetics have been given safely and
effectively to minimize the otherwise deleterious side effects of
major invasive procedures. Despite such success, their exact
mechanism remains elusive. This is confounded by the fact that our
understanding of the conscious state which general anesthesia
alters is grossly inadequate. However, over the past years, great
insights have been gained into the molecular underpinnings of
anesthetic mechanisms, just as they have with comparable factors
within the central nervous system. It is now believed that
anesthetics mediate a significant portion of their activity via
binding to and modulation of transmembrane ligand-gated ion
channels (LGICs). In particular, the gamma-aminobutyric acid
receptor type A (GABAaR) and the glycine alpha one receptor
(GlyRa1) are ion channels whose inhibitory currents are potentiated
by the presence of general anesthetics. It is the GABAaR whose
perturbation by barbiturates and benzodiazepines produces a state
strongly similar to general anesthesia. Likewise, the intravenous
general anesthetics, propofol and etomidate, are thought to
modulate consciousness through specific sites within these
channels. Jurd et al. (2003) Faseb J 17:250-2. These ion channels
are composed of five subunits, often heteropentameric and variable
in stoichiometry, arranged around a central ion conducting pore.
The extracellular domain of a representative subunit is
characterized by a large component of beta sheet secondary
structure and contains the binding site for the native ligand
germane to the channel in question (i.e. gamma-aminobutyric acid
(GABA) for the GABAaR). The transmembrane domain is composed
largely of four-helix bundles. This latter secondary structure is a
significant feature predicted in the inventors' laboratory and
later validated by experimentalists. Bertaccini et al. (2002)
Protein Eng 15:443-54; Miyazawa et al. Nature 424:949-55. It is
within this transmembrane region that anesthetics and alcohols are
thought to bind and convey the majority of their channel
modulation. Bertaccini et al. (2010) J Chem Inf Model
50:2248-55.
[0003] The LGICs are transmembrane proteins, and their isolation
and purification has thus proven difficult. While a recently
published crystal structure shows the homomeric GABAaR beta 3 in
the desensitized state (Miller et al. (2014) Nature 512:270-5) (a
state that is insensitive to most anesthetics and alcohols), high
resolution crystal structures of the heteromeric GABAaR in the open
state (a state that anesthetics are thought to stabilize) do not
exist. However, molecular modeling approaches are beginning to
provide significant progress towards an understanding of LGIC
structure and the interactions of these proteins with
anesthetics.
[0004] The mainstay of such calculations lies in the techniques of
homology modeling. Homology modeling is the method by which the
amino acid sequence of a protein of unknown structure is aligned
and threaded over that of a closely related amino acid sequence
with known three-dimensional structure, such that the coordinates
of the known protein can be transferred to those of the unknown.
While such homology modeling involves a great deal of computational
theory, it is also very dependent on experimentally described
coordinates of proteins to act as templates with high sequence
homology to the desired protein. Bertaccini et al. (2010) J Chem
Inf Model 50:2248-55; Murail et al. (2011) Biophys J 100:1642-50.
Over the last several years, several templates with great homology
to the LGICs have been determined via cryo-electron microscopy,
X-ray crystallography, and nuclear magnetic resonance (NMR) that
have made model construction more robust.
[0005] The inventors' new models, based on such a template, can
account for much of the currently available experimental data
concerning these channels, allowing correlation of ligand binding
measures with experimental potencies. These models have been used
to illustrate the mechanism of channel gating (Bertaccini et al.
(2010) ACS Chem. Neurosci. 1:552-558; Szarecka et al. (2007)
Proteins 68:948-60) and can be used as the bases for in silico high
throughput screening and new anesthetic discovery, and, in
particular, to identify lead compounds for further screening in
animals.
[0006] An April 2010 statement by MarketResearch.com reported that
the world anesthetic drug market is estimated to be $4.1 billion.
The drug profiles and dangerous side effects of the currently
available agents are many, however, especially amongst the aging
population of geriatric patients. Proportionately, the fastest
growing segment of the population are octagenerians and older, a
group of people who are now responsible for the majority of
healthcare expenditures and are in need of increasing surgical and
anesthetic care. Therefore, there is significant clinical pressure
as well as market opportunity to develop new anesthetic agents.
[0007] There are currently four main intravenous and three primary
inhalational anesthetic agents which are in common clinical use.
Each of these agents is associated with an entire spectrum of
undesirable hemodynamic perturbations, most of which result in
lower systemic blood pressure. This is a side effect that is poorly
tolerated in the very young patient, with newly developing
cardiovascular compensatory mechanisms, as well as in the elderly,
with confounding comorbidities and otherwise exhausted compensatory
mechanisms.
[0008] Each of the commonly-used anesthetic agents has additional
unique detriments. In particular, etomidate is the agent which
comes closest to achieving ideal cardiovascular preservations while
inducing dose-dependent alterations in consciousness, but this is
at the expense of clinically significant adrenal suppression via
inhibited steroid biosynthesis. U.S. Pat. No. 8,557,856 describes
etomidate analogues having alleged improved pharmacokinetic and
pharmacodynamics properties. U.S. Pat. No. 8,765,973 describes
etomidate analogues that allegedly do not inhibit steroid
biosynthesis. None of these etomidate analogues has yet achieved
clinical approval, however.
[0009] Propofol has gained wide popularity, but in the past few
years has been the subject of a nationwide shortage and can produce
profound hypotension. While no profit estimates can be given for
new anesthetic agents at this time, the cost savings from greater
titratability and minimal cardiopulmonary side effects, both of
which should lead to shorter and less complicated hospital stays,
would be substantial.
[0010] There is thus a need for improved anesthetic agents,
particularly for use in very young patients, elderly patients, and
in patients that are critically ill. There is likewise a need for
pharmaceutical compositions containing the improved agents and for
methods of treatment that involve administration of the agents to
induce or maintain anesthesia.
SUMMARY OF THE INVENTION
[0011] The present invention addresses these and other problems by
providing compounds, pharmaceutical compositions, kits, and methods
of use of compounds that act as anesthetics.
[0012] In particular, according to one aspect of the invention,
methods of treatment are provided that comprise administering to a
subject in need thereof a concentration of a compound sufficient to
induce or maintain anesthesia in the subject, wherein the compound
is represented by structural formula (I):
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein: R.sub.i1
and R.sub.i2 are independently H, a lower alkyl group, or a phenyl
group, wherein the alkyl group and phenyl group are optionally and
independently substituted with one or more alkyl, alkenyl, alkynyl,
alkoxy, alkanoyl, alkylamino, alkylthio, aryl, aryloxy, arylamino,
aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl,
heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy,
heteroaralkanoyl, heteroaralkamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido groups, and wherein two adjacent substituent
groups can combine to form a ring;
[0013] either R.sub.i3 or R.sub.i4 is --C(O)OR.sub.e, and the other
group is H or a lower alkyl group;
[0014] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido; and
[0015] R.sub.i5 is a phenyl group optionally substituted with one
or more alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring.
[0016] Also provided are methods of treatment, wherein the compound
is represented by structural formula (II):
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein:
[0017] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, alkylcarboxy,
alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido;
[0018] R.sub.i3 is H or a lower alkyl group; and
[0019] R.sub.i1, R.sub.i2, and R.sub.e are as defined above for
structural formula (I).
[0020] In some of the methods, the compound is represented by
structural formula (III):
##STR00003##
or a pharmaceutically acceptable salt thereof, wherein:
[0021] R.sub.p1, R.sub.p2, R.sub.p3, and R.sub.p4 are independently
H, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
alkylcarboxy, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl,
carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido;
[0022] R.sub.i3 is H or a lower alkyl group; and
[0023] R.sub.i1 and R.sub.e are as defined above for structural
formula (I).
[0024] In another aspect, compounds are provided as represented by
structural formula (II):
##STR00004##
or a pharmaceutically acceptable salt thereof, wherein:
[0025] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0026] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0027] R.sub.i2 is a phenyl group optionally substituted with one
or more alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring;
[0028] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0029] R.sub.e is C.sub.3-C.sub.8-alkyl, alkenyl, alkynyl, aryl,
aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl,
heterocyclyl, or heterocyclylalky, and is optionally substituted
with alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido;
[0030] provided that when R.sub.i1 is methyl, R.sub.i2 is
unsubstituted phenyl, and R.sub.e is benzyl, isopropyl, isobutyl,
t-butyl, methoxyethyl, or 4,4-difluoro-3-methyl-3-buten-1-yl, and
R.sub.p1 is H, then R.sub.p2 is not H;
[0031] when R.sub.i1 is methyl, R.sub.i2 is 2-methoxyphenyl,
R.sub.e is t-butyl, and R.sub.p1 is H, then R.sub.p2 is not H,
3-amino, 3-azido, 4-bromo, or 4-nitro; and
[0032] when R.sub.i1 is methyl, R.sub.i2 is 2-methoxyphenyl,
R.sub.e is benzyl, and R.sub.p1 is H, then R.sub.p2 is not H.
[0033] In another aspect, compounds are provided as represented by
structural formula (II):
##STR00005##
or a pharmaceutically acceptable salt thereof, wherein:
[0034] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0035] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0036] R.sub.i2 is a phenyl group substituted with one or more
alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio,
aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring;
[0037] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0038] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0039] provided that R.sub.i2 is not 2-aminophenyl, 3-aminophenyl,
3-amino-4-hydroxyphenyl, 4-aminophenyl, 3-azidophenyl,
1,1'-biphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-carboxyphenyl, 2-(chlorocarbonyl)phenyl, 4-chlorophenyl,
2,4-dichlorophenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl,
3,4-dimethylphenyl, 4-fluorophenyl, 2-methoxyphenyl,
3-methoxyphenyl, 4-methoxyphenyl, 3-(ethoxycarbonyl)phenyl,
4-(methoxycarbonyl)phenyl, 2-methylphenyl, 4-methylphenyl,
4-(methylsulfonyl)phenyl, 4-(methylthio)phenyl,
3-(4-morpholinylsulfonyl)phenyl, 2-nitrophenyl, 3-nitrophenyl,
4-nitrophenyl, 3-(phenylamino)phenyl, 4-(1H-pyrrol-1-yl)phenyl,
4-(1-methyl-1H-pyrazol-4-yl)phenyl, 2-hydroxy-5-aminophenyl, or
4-[5-(4-chlorophenyl)-3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]phenyl].
[0040] In still another aspect, compounds are provided as
represented by structural formula (IV):
##STR00006##
or a pharmaceutically acceptable salt thereof, wherein:
[0041] R.sub.p3 and R.sub.p4 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0042] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0043] R.sub.i5 is a phenyl group substituted with one or more
alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido groups;
[0044] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0045] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0046] provided that R.sub.i5 is not 2-aminophenyl, 2-bromophenyl,
2-carboxyphenyl, 2-chlorophenyl, 2-(dimethylamino)phenyl,
2-ethylphenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 2-methylphenyl,
2-nitrophenyl, 2-trifluoromethylphenyl, 3-acetylphenyl,
3-aminophenyl, 3-aminocarbonylphenyl, 3-azidophenyl, 3-bromophenyl,
3-butoxyphenyl, 3-carboxyphenyl, 3-chlorophenyl,
3-(dimethylamino)phenyl, 3-fluorophenyl, 3-hydroxylphenyl,
3-iodophenyl, 3-methoxyphenyl, 3-methylphenyl, 3-methylthiophenyl,
3-nitrophenyl, 3-trifluoromethylphenyl, 4-aminophenyl,
4-azidophenyl, 4-bromophenyl, 4-carboxyphenyl, 4-chlorophenyl,
4-ethoxyphenyl, 4-ethylphenyl, 4-fluorophenyl, 4-hydroxyphenyl,
4-methoxyphenyl, 4-methylphenyl, 4-nitrophenyl,
4-trifluoromethoxyphenyl, 4-(3,3,3-trifluoropropoxy)phenyl,
2,4-difluorophenyl, 2,4-dichlorophenyl, 3-amino-4-hydroxyphenyl,
3-carboxy-4-hydroxyphenyl, 2-hydroxy-5-aminophenyl,
2-bromo-4-acetylphenyl, 2,4-dibromophenyl,
2-bromo-4-(ethoxycarbonyl)phenyl, 2-bromo-4-fluorophenyl,
2-bromo-4-trifluoromethylphenyl, 3-hydroxy-4-carboxyphenyl,
3-carboxy-4-hydroxyphenyl, 2,6-diisopropylphenyl,
2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,3-dimethylphenyl,
2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl,
3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-methoxy-4-methylphenyl,
2-methyl-3-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl,
3,5-dichlorophenyl, 2-methoxy-5-nitrophenyl,
2-nitro-4-methylphenyl, or 2-chloro-5-trifluoromethylphenyl.
[0047] In yet another aspect, compounds are provided as represented
by structural formula (II):
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein:
[0048] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0049] R.sub.i1 is H;
[0050] R.sub.i2 is a phenyl group optionally substituted with
alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio,
aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido, and wherein two adjacent
substituent groups can combine to form a ring;
[0051] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0052] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0053] provided that when R.sub.i2 is 4-(methylsulfonyl)phenyl,
R.sub.e is methyl, and R.sub.p1 is H, then R.sub.p2 is not
4-fluoro; and
[0054] when R.sub.i2 is unsubstituted phenyl, R.sub.e is methyl,
and R.sub.p1 is H, then R.sub.p2 is not 4-methoxy.
[0055] According to another aspect of the invention are provided
pharmaceutical compositions comprising any of the compounds of the
invention and a pharmaceutically acceptable carrier, as well as
packaged pharmaceuticals comprising these pharmaceutical
compositions and instructions for using the compositions to treat a
mammalian subject.
BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG. 1. (A) Prior art compound disclosed by Mascia et al.
(2005) Eur. J. Pharmacol. 516:204-211 (designated herein as
compound "TG41" or "1n"). (B) Novel compound (designated herein as
compound "carbo-1n") designed to avoid inhibition of corticosteroid
biosynthesis.
[0057] FIG. 2. (A) Illustrates a 3-dimensional model of the GABA
receptor, including the transmembrane domain, the extracellular
domain, and the GABA binding site. (B) Shows a cross-section of the
receptor model in the region of the proposed anesthetic binding
site. (C) Shows a detailed structural model around the residues
believed to be involved in modulating anesthetic action, as well as
a bound molecule of propofol at this site.
[0058] FIG. 3. Results of the docking of propofol analogues, using
the CDocker Interaction Energy score (CDIE).
[0059] FIG. 4. Plot of negative CDocker interaction energy as a
function of the logarithm of GABAaR EC.sub.50.
[0060] FIG. 5. (A) Model of the most likely orientation of carbo-1n
in relation to the heme iron of the FAD moiety within the binding
site of 11-beta hydroxylase. (B) Model of the most likely
orientation of compound 1n in relation to the same heme iron. Note
the proximity of the imidazole nitrogen in compound in to the heme
iron, which allows the covalent binding between the two and the
lack of such binding in carbo-1n.
[0061] FIG. 6. Dose-response curves for the effects of compounds A
(panel A) and B (panel B) in the tadpole Loss of Righting Reflex
assays. The units of the x-axis are log(.mu.M).
[0062] FIG. 7. Effect of compound B on a hippocampal brain slice
preparation.
DETAILED DESCRIPTION OF THE INVENTION
[0063] Anesthetics are understood to mediate at least part of their
activity via modulation of the gamma-aminobutyric acid type A
receptor (GABAaR). While the molecular structure of this receptor
remains unknown, significant progress has been made towards
understanding the interaction of the receptor with anesthetics via
molecular modeling. Consensus structural alignment based on
homologous templates with subsequent homology modeling reveals an
intersubunit anesthetic binding cavity within the transmembrane
domain of the GABAaR. As described herein, this binding site model
reveals the correlation of in silico ligand docking scores with
experimentally measured GABAaR potentiation for a series of
propofol-like derivatives. Further screening of a series of highly
potent etomidate-like derivatives also reveals a strong correlation
between ligand binding scores and experimental GABAaR potentiation.
However, these latter derivatives contain an exposed imidazole
nitrogen which can be shown in the inventors' modeling to be
capable of binding to and potentially irreversibly inhibiting the
enzyme, 11-beta hydroxylase, an effect well known to occur with
etomidate itself. In light of this, the inventors have created a
version of the most potent of the previously-described
etomidate-like derivatives in silico (containing a carbon
substituted for the imidazole nitrogen, now referred to as
carbo-1n). See FIG. 1B. As disclosed herein, the inventors have
successfully shown in silico the inability of this compound to
modify 11-beta hydroxylase despite temporary binding site
occupancy, while showing strong binding scores to the anesthetic
binding site within the inventors' model of the GABAaR. A further
search has been made of known chemical structures for compounds
having similar properties to carbo-1n. Accordingly, 12 existing
compounds were identified by the inventors and subsequently
successfully docked to the anesthetic binding site within the
GABAaR model. These agents have been tested in tadpoles for their
ability to induce the loss of righting reflex (a surrogate measure
of the anesthetized state in tadpoles) and have been used in
further mechanistic analyses via hippocampal slice
electrophysiology. These studies have revealed a mechanism of
action of the novel anesthetic agents consistent with GABAaR
activity.
[0064] A new class of active anesthetic compounds has thus been
identified by the inventors and described in the instant
disclosure. Compounds within this class have not previously been
associated with, or known to produce, anesthetic effects. These
compounds are expected to provide potent clinical efficacy in
producing states ranging from sedation to general anesthesia via
high selectivity and affinity to receptors known to modulate
consciousness. They are also expected to provide minimal
cardiopulmonary perturbations, minimal to no toxicity, and kinetics
favorable for rapid titratability. They are synthetically
accessible with current processes or predictable new synthetic
methodologies. As noted above, the currently-approved anesthetics
cannot satisfy all these ideal features. Any attempt to derive a
more ideal anesthetic is predicated on the identification and
development of new chemical core structures that have the desired
anesthetic activity in a process of scaffold hopping, as has now
been demonstrated in the work provided herein.
[0065] Sophisticated molecular computations, previously only
available via supercomputing facilities, can now be achieved with
advanced desktop workstations. Software development has taken full
advantage of high-end 3D visualization, as well as highly
parallelized computational algorithms, for efficient drug screening
methodologies. Concurrent with this, the inventors' understanding
of the molecular substrates for conscious states has also advanced
in the form of robust models of the ligand-gated ion channels that
mediate particular anesthetic actions. See, for example, Bertaccini
et al. (2010) J Chem Inf Model 50:2248-55; Murail et al. (2011)
Biophys J 100:1642-50; Bertaccini et al. (2010) ACS Chem. Neurosci.
1:552-558; Bertaccini (2010) Pharmaceuticals 3:2178-2196;
Bertaccini et al. (2010) Anesthesiology A1312. As presented here,
this knowledge has been used to leverage the advances in
computational capabilities for high throughput in silico screening
(via ligand-receptor docking methodologies, fragment-based drug
design, and in silico pre-clinical toxicity prediction
technologies) in performing efficient lead identification and drug
design using proteins that are known to bind anesthetics and/or
that are involved in neuronal processes of consciousness (i.e. the
inventors' current state-of-the-art molecular models of
ligand-gated ion channels-LGICs).
Methods of Treatment
[0066] According to one aspect, the invention thus provides novel
methods of treatment that comprise administering to a subject in
need thereof a concentration of a compound sufficient to induce or
maintain anesthesia in the subject. The subject anesthetic compound
may be administered by any route suitable for achieving the desired
effect. For example, the anesthetic may be administered orally,
intravenously, inhalationally, subcutaneously, intramuscularly,
transdermally, topically, or by any other suitable route.
[0067] Compounds for use in the instant methods may be represented
by structural formula (I):
##STR00008##
[0068] or a pharmaceutically acceptable salt thereof, wherein:
[0069] R.sub.i1 and R.sub.i2 are independently H, a lower alkyl
group, or a phenyl group, wherein the alkyl group and phenyl group
are optionally and independently substituted with alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl, aryloxy,
arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl,
heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy,
heteroaralkanoyl, heteroaralkamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido, and wherein two adjacent substituent groups
can combine to form a ring; [0070] either R.sub.i3 or R.sub.i4 is
--C(O)OR.sub.e, and the other group is H or a lower alkyl group;
[0071] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido; and [0072] R.sub.i5 is a phenyl group
optionally substituted with alkyl, alkenyl, alkynyl, alkoxy,
alkanoyl, alkylamino, alkylthio, aryl, aryloxy, arylamino, aralkyl,
aralkoxy, aralkanoyl, aralkamino, heteroaryl, heteroaryloxy,
heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl,
heteroaralkamino, cycloalkyl, cycloalkenyl, cycloalkoxy,
cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy,
heterocyclylamino, heterocyclylalky, heterocyclylalkoxy,
heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino,
amido, alkanoylamino, aroylamino, aralkanoylamino, alkylcarboxy,
alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido, and wherein two
adjacent substituent groups can combine to form a ring.
[0073] In some embodiments, in the compounds of structural formula
(I), either of R.sub.i1 and R.sub.i2 is an optionally substituted
phenyl group, and the other is H or an unsubstituted lower alkyl
group. In more specific embodiments, the R.sub.i1 or R.sub.i2
optionally substituted phenyl group is optionally substituted with
an alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido group. In still more
specific embodiments, the R.sub.i1 or R.sub.i2 optionally
substituted phenyl group is optionally substituted with an alkyl,
alkoxy, or halo group. In other embodiments, R.sub.i1 and R.sub.i2
is each independently an unsubstituted lower alkyl group.
[0074] In some embodiments, R.sub.e is an optionally substituted
lower alkyl or aralkyl group, and more specifically, R.sub.e is an
optionally substituted lower alkyl group.
[0075] The R.sub.i5 phenyl group may in certain embodiments be
optionally substituted with an alkyl, alkoxy, hydroxyl, thio,
amino, carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido group. In specific embodiments, R.sub.i5 is a phenyl group
optionally substituted with an alkyl, alkoxy, or halo group.
[0076] In certain embodiments of the instant methods of treatment,
for compounds having structural formula (I), either of R.sub.i1 and
R.sub.i2 is a phenyl group optionally substituted with an alkyl,
alkoxy, hydroxyl, thio, amino, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido group, and the other of R.sub.i1
and R.sub.i2 is H or an unsubstituted lower alkyl group;
[0077] R.sub.e is an optionally substituted lower alkyl or aralkyl
group; and
[0078] R.sub.i5 is a phenyl group optionally substituted with an
alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido group.
[0079] In more specific method embodiments, the compound is
represented by structural formula (II):
##STR00009##
or a pharmaceutically acceptable salt thereof, wherein:
[0080] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, alkylcarboxy,
alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, carboxy,
carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano,
nitro, phosphoryl, sulfonyl, sulfonamido, or azido;
[0081] R.sub.i3 is H or a lower alkyl group; and
[0082] R.sub.i1, R.sub.i2, and R.sub.e are as defined above for
structural formula (I). More specifically, R.sub.p1 and R.sub.p2
are independently H, alkyl, alkoxy, or halo.
[0083] In some embodiments, either of R.sub.i1 and R.sub.i2 is an
optionally substituted phenyl group, and the other is H or an
unsubstituted lower alkyl group. More specifically, the R.sub.i1
and R.sub.i2 optionally substituted phenyl group is substituted
with an alkyl, alkoxy, or halo group.
[0084] For compounds of structural formula (II) in certain method
embodiments, R.sub.i1 and R.sub.i2 is each independently an
unsubstituted lower alkyl group. In some embodiments, R.sub.e is an
optionally substituted lower alkyl or aralkyl group or is an
optionally substituted lower alkyl group.
[0085] In some method embodiments, the compound is represented by
structural formula (III):
##STR00010##
or a pharmaceutically acceptable salt thereof, wherein:
[0086] R.sub.p1, R.sub.p2, R.sub.p3, and R.sub.p4 are independently
H, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
alkylcarboxy, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl,
carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido;
[0087] R.sub.i3 is H or a lower alkyl group; and
[0088] R.sub.i1 and R.sub.e are as defined above for structural
formula (I). Specifically, R.sub.p1, R.sub.p2, R.sub.p3, and
R.sub.p4 may be independently H, alkyl, alkoxy, or halo.
[0089] In other embodiments, in the compound of structural formula
(III), R.sub.i1 is lower alkyl. In still other embodiments,
R.sub.i3 is H. In still yet other embodiments, R.sub.e is an
optionally substituted lower alkyl or aralkyl group.
[0090] In the instant methods of treatment, the anesthetic compound
is administered at a dose sufficient to achieve a desired
anesthetic endpoint, for example amnesia, analgesia,
unconsciousness, or immobility. Administered dosages for the
anesthetic compound are in accordance with dosages and scheduling
regimens practiced by those of skill in the art. General guidance
for appropriate dosages of pharmacological agents used in the
present methods is provided in Goodman and Gilman's The
Pharmacological Basis of Therapeutics, 12th Edition (2010), and in
Physicians' Desk Reference, 68.sup.t Edition, each of which is
hereby incorporated herein by reference.
[0091] The appropriate dosage of a particular anesthetic compound
will vary according to several factors, including the chosen route
of administration, the formulation of the composition, patient
response, the severity of the condition, the subject's weight, the
susceptibility of the subject to side effects, and the judgment of
the prescribing physician. The dosage may be increased or decreased
over time, as required by an individual subject. Preferred dosages
for a given compound are readily determinable by those of ordinary
skill in the art by a variety of means. Dosage amount and interval
may be adjusted individually to provide plasma levels of the active
compounds which are sufficient to maintain a desired therapeutic
effect.
[0092] In one embodiment, the anesthetic compound is administered
in an amount of about 1 .mu.g to 1000 mg per dose, e.g., about 1
.mu.g to 5 .mu.g, about 5 .mu.g to 10 .mu.g, about 10 .mu.g to 50
.mu.g, about 50 .mu.g to 100 .mu.g, about 100 .mu.g to 200 .mu.g,
about 200 .mu.g to 400 .mu.g, about 400 .mu.g to 800 .mu.g, about
800 .mu.g to 1 mg, about 1 mg to 2 mg, about 2 mg to 4 mg, about 4
mg to 8 mg, about 8 mg to 10 mg, about 10 mg to 20 mg, about 20 mg
to 40 mg, about 40 mg to 80 mg, about 80 mg to 100 mg, about 100 mg
to 2000 mg, about 200 mg to 400 mg, about 400 mg to 1000 mg per
dose, or even higher.
[0093] In another embodiment, the amount of the anesthetic compound
administered per dose is determined on a per body weight basis. For
example, the amount of the compound or composition per dose, as
determined on a per body weight basis, may be, for example, about
10 ng/kg, about 15 ng/kg, about 20 ng/kg, about 50 ng/kg, about 100
ng/kg, about 200 ng/kg, about 500 ng/kg, about 1 g/kg, about 2
.mu.g/kg, about 5 .mu.g/kg, about 10 .mu.g/kg, about 20 .mu.g/kg,
about 50 g/kg, about 100 .mu.g/kg, about 200 .mu.g/kg, about 500
.mu.g/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10
mg/kg, or even higher.
[0094] In an embodiment, multiple doses of the anesthetic compound
are administered. The frequency of administration of the compound
may vary depending on any of a variety of factors, e.g., severity
of the symptoms, and the like. For example, in an embodiment, the
compound is administered once per month, twice per month, three
times per month, every other week (qow), once per week (qw), twice
per week (biw), three times per week (tiw), four times per week,
five times per week, six times per week, every other day (qod),
daily (qd), twice a day (bid), or three times a day (tid). In some
embodiments, for example during a surgical procedure, the compound
may be administered even more frequently. For example, the compound
may be administered at least once per four hours, at least once per
two hours, at least once per hour, at least twice per hour, at
least four times per hour, at least 10 times per hour, or even more
frequently.
[0095] In some embodiments, the compound is administered
continuously. The duration of administration of the anesthetic
compound, e.g., the period of time over which the compound is
administered, may vary, depending on any of a variety of factors,
e.g., the chosen route of administration, the formulation of the
composition, patient response, and so forth. For example, the
compound may be administered over a period of time of at least 5
minutes, at least 30 minutes, at least one hour, at least 2 hours,
at least 4 hours, at least 8 hours, at least one day, at least one
week, or even longer. In other embodiments, the compound may be
administered over a period of time of no more than one week, no
more than one day, no more than 8 hours, no more than 4 hours, no
more than 2 hours, no more than one hour, no more than 30 minutes,
no more than 5 minutes, or even shorter. In some embodiments, the
compound may be administered for a time period of about 5 minutes
to 30 minutes, of about 30 minutes to one hour, of about one hour
to 2 hours, of about 2 hours to 4 hours, of about 4 hours to 8
hours, of about 8 hours to one day, or of about one day to one
week.
[0096] In various embodiments, the anesthetic compounds are
delivered to the subject via the respiratory pathway, e.g., via
inhalational, pulmonary and/or intranasal delivery. Technologies
and devices for inhalational anesthetic drug dosing are known in
the art. They are described, for example, in Miller's Anesthesia
(2009), edited by Ronald D. Miller, et al., 2 vols, 7th ed,
Philadelphia, Pa., Churchill Livingstone/Elsevier. In one
embodiment, the anesthetic compounds are administered to deliver a
dose of between about 0.1-10.0 percent of 1 atmosphere (1 atm),
e.g., 0.5-5.0 percent of 1 atm, e.g., about 1.0-3.5 of 1 atm, e.g.,
about 0.1, 0.2, 0.3, 0.4. 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0,
4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 or 10.0
percent of 1 atm, e.g., delivered over the period of time of
desired anesthesia. The dose used will be dependent upon the drug
potency, and the compound or mixture of compounds administered.
[0097] Detailed information about the delivery of therapeutically
active anesthetic agents in the form of vapors or gases is
available in the art. The anesthetic compound will typically be
vaporized using a vaporizer using a carrier gas such as oxygen,
air, or helium, or a mixture thereof, to achieve a desired
concentration suitable for inhalation by use of a semi-open or
semi-closed anesthetic circuit, as is known to those of ordinary
skill in the art. The anesthetic compound, in gaseous form, may
also be directly mixed with a carrier gas such as oxygen, air, or
helium, or a mixture thereof, to achieve a desired concentration
suitable for inhalation by use of a semi-open or semi-closed
anesthetic circuit, as is understood by the skilled artisan. The
anesthetic compound may also be administered by direct application
onto or through a breathing mask, also termed an open circuit. In
animal subjects, the compound may also be administered into a
closed chamber or container containing the animal subject whereby
the compound is delivered by the respiratory tract as the animal
breathes, as is known to those of ordinary skill in the art.
[0098] In some aspects of the invention, the anesthetic compound or
mixture of compounds, is dissolved or suspended in a suitable
solvent, such as water, ethanol, or saline, and administered by
nebulization. A nebulizer produces an aerosol of fine particles by
breaking a fluid into fine droplets and dispersing them into a
flowing stream of gas. Medical nebulizers are designed to convert
water or aqueous solutions or colloidal suspensions to aerosols of
fine, inhalable droplets that can enter the lungs of a subject
during inhalation and deposit on the surface of the respiratory
airways. Typical pneumatic (compressed gas) medical nebulizers
develop approximately 15 to 30 microliters of aerosol per liter of
gas in finely divided droplets with volume or mass median diameters
in the respirable range of 2 to 4 micrometers. Predominantly, water
or saline solutions are used with low solute concentrations,
typically ranging from 1.0 to 5.0 mg/mL.
[0099] Nebulizers for delivering an aerosolized solution to the
lungs are commercially available from a number of sources,
including the AERx.TM. (Aradigm Corp., Hayward, Calif.) and the
Acorn II.RTM. (Vital Signs Inc., Totowa, N.J.).
[0100] Metered dose inhalers are also known and available.
Breath-actuated inhalers typically contain a pressurized propellant
and provide a metered dose automatically when the patient's
inspiratory effort either moves a mechanical lever or the detected
flow rises above a preset threshold, as detected by a hot wire
anemometer. See, for example, U.S. Pat. Nos. 3,187,748; 3,565,070;
3,814,297; 3,826,413; 4,592,348; 4,648,393; 4,803,978; and
4,896,832.
[0101] In various other embodiments, the anesthetic compounds of
the instant disclosure are delivered to the subject via injection.
The compounds are preferably formulated, as described below, in
compositions that facilitate the effective delivery of the injected
compounds to the nervous system. In particular, and as described
below, the compositions are preferably delivered in the instant
methods of treatment by parenteral administration, as is well
understood in the art.
[0102] In some embodiments, the present invention provides methods
of treatment that induce or maintain tranquilization or sedation in
a subject. For example, seriously ill subjects, such as patients in
an intensive care unit, may be sedated according to the instant
methods, for example by continuous infusion of a solution
comprising one or more of the instant anesthetic compounds. In more
specific embodiments, the methods induce or maintain
tranquilization in a subject. In some other embodiments, the
methods induce or maintain amnesia in a subject. Typically, the
amount of a compound that is required to induce or maintain amnesia
in a subject is larger than the amount required to induce or
maintain tranquilization in the subject. In yet other embodiments,
the invention provides methods to induce or maintain a hypnotic
state in a subject. Typically, the amount of an anesthetic compound
that is required to induce or maintain a hypnotic state in a
subject is larger than the amount required to induce or maintain
amnesia in the subject. In still other embodiments, the invention
provides methods that induce or maintain a state of insensitivity
to noxious stimulation in a subject. Typically, the amount of an
anesthetic compound that is required to induce or maintain a state
of insensitivity to noxious stimulation in a subject is larger than
the amount required to induce or maintain a hypnotic state in the
subject.
[0103] The present invention includes methods of inducing or
maintaining a spectrum of states of anesthesia in a subject as a
function of the administered dosage of an anesthetic compound
disclosed herein. In some embodiments, the methods include
administering low dosages of a compound to induce or maintain
tranquilization or sedation in a subject. In some other
embodiments, the methods include administering higher dosages than
that required to induce or maintain tranquilization of a compound
or a mixture of compounds which are described herein to induce
amnesia in a subject. In yet other embodiments, the methods include
administering even higher dosages than that required to induce
amnesia in a subject of a compound or a mixture of compounds which
are described herein to induce a hypnotic state in a subject. In
still other embodiments, the methods include administering yet even
higher dosages than that required to induce a hypnotic state in a
subject of a compound or a mixture of compounds which are described
herein to induce a state of insensitivity to noxious stimulation in
a subject.
[0104] In some embodiments, the present invention provides methods
of treatment of pain in a subject. In some pain treatment
embodiments, the anesthetic compound is delivered topically. In
other pain treatment embodiments, the anesthetic compound is
delivered systemically.
Compounds
[0105] According to another aspect of the invention, novel
compounds are provided that display anesthetic effects on animal
subjects. A first category of compounds is represented by
structural formula (II):
##STR00011##
or a pharmaceutically acceptable salt thereof, wherein:
[0106] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0107] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0108] R.sub.i2 is a phenyl group optionally substituted with one
or more alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring;
[0109] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0110] R.sub.e is C.sub.3-C.sub.8-alkyl, alkenyl, alkynyl, aryl,
aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl,
heterocyclyl, or heterocyclylalky, and is optionally substituted
with alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido;
[0111] provided that when R.sub.i1 is methyl, R.sub.i2 is
unsubstituted phenyl, and R.sub.e is benzyl, isopropyl, isobutyl,
t-butyl, methoxyethyl, or 4,4-difluoro-3-methyl-3-buten-1-yl, and
R.sub.p1 is H, then R.sub.p2 is not H;
[0112] when R.sub.i1 is methyl, R.sub.i2 is 2-methoxyphenyl,
R.sub.e is t-butyl, and R.sub.p1 is H, then R.sub.p2 is not H,
3-amino, 3-azido, 4-bromo, or 4-nitro; and
[0113] when R.sub.i1 is methyl, R.sub.i2 is 2-methoxyphenyl,
R.sub.e is benzyl, and R.sub.p1 is H, then R.sub.p2 is not H.
[0114] As used herein, the term "alkyl" refers to the radical of
saturated aliphatic groups, including straight-chain alkyl groups,
branched-chain alkyl groups, cycloalkyl (alicyclic) groups,
alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted
alkyl groups. In some embodiments, a straight chain or branched
chain alkyl has 30 or fewer carbon atoms in its backbone (e.g.,
C.sub.1-C.sub.30 for straight chains, C.sub.3-C.sub.30 for branched
or cyclic chains), more specifically 20 or fewer carbon atoms in
its backbone (e.g., C.sub.1-C.sub.20 for straight chains,
C.sub.3-C.sub.20 for branched or cyclic chains), and even more
specifically 10 or fewer carbon atoms in its backbone (e.g.,
C.sub.1-C.sub.10 for straight chains, C.sub.3-C.sub.10 for branched
or cyclic chains). Likewise, some cycloalkyls have from 3-10 carbon
atoms in their ring structure, and more specifically have 5, 6 or 7
carbons in the ring structure.
[0115] Moreover, the term "alkyl" (or "lower alkyl") as used
throughout the specification, examples, and claims is intended to
include both "unsubstituted alkyls" and "substituted alkyls", the
latter of which refers to alkyl moieties having substituents
replacing a hydrogen on one or more carbons of the hydrocarbon
backbone. Such substituents may include, for example, a halo, a
hydroxyl, a carbonyl (such as a keto, a carboxy, an alkoxycarbonyl,
a formyl, an acyl, a carbonate, a carbamate, an ester, or a urea),
a thiocarbonyl (such as a thioester, a thioacetate, or a
thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate,
a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a
nitro, an azido, a thio, an alkylthio, a sulfate, a sulfonate, a
sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl,
or an aromatic or heteroaromatic moiety. It will be understood by
those skilled in the art that the moieties substituted on the
hydrocarbon chain can themselves be substituted, if appropriate.
For instance, the substituents of a substituted alkyl may include
substituted and unsubstituted forms of amino, azido, imino, amido,
phosphoryl (including phosphonate and phosphinate), sulfonyl
(including sulfate, sulfonamido, sulfamoyl and sulfonate), and
silyl groups, as well as ethers, alkylthios, carbonyls (including
ketones, aldehydes, carboxylates, and esters), --CF.sub.3, --CN,
halo, and the like. Exemplary substituted alkyls are described
below. Cycloalkyls can be further substituted with alkyls,
alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted
alkyls, --CF.sub.3, --CN, halo, and the like.
[0116] As used herein, the term "alkoxy" refers to an oxy group
substituted with an alkyl group, in certain specific embodiments, a
lower alkyl group. Representative alkoxy groups include methoxy,
ethoxy, propoxy, t-butoxy, and the like.
[0117] The term "alkenyl", as used herein, refers to an aliphatic
group containing at least one double bond and is intended to
include both "unsubstituted alkenyls" and "substituted alkenyls",
the latter of which refers to alkenyl moieties having substituents
replacing a hydrogen on one or more carbons of the alkenyl group.
Such substituents may occur on one or more carbons that are
included or not included in one or more double bonds. Moreover,
such substituents include all those contemplated for alkyl groups,
as discussed above, except where stability is prohibitive. For
example, substitution of alkenyl groups by one or more alkyl,
cycloalkyl, heterocyclyl, aryl, or heteroaryl groups is
contemplated.
[0118] The term "C.sub.x-y" when used in conjunction with a
chemical moiety, such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or
alkoxy, is meant to include groups that contain from x to y carbons
in the chain. For example, the term "C.sub.x-y-alkyl" refers to
substituted or unsubstituted saturated hydrocarbon groups,
including straight-chain alkyl and branched-chain alkyl groups that
contain from x to y carbons in the chain, including haloalkyl
groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.
"C.sub.0-alkyl" indicates a hydrogen where the group is in a
terminal position, or is a bond if internal. The terms
"C.sub.2-y-alkenyl" and "C.sub.2-y-alkynyl" refer to substituted or
unsubstituted unsaturated aliphatic groups analogous in length and
possible substitution to the alkyls described above, but that
contain at least one double or triple bond, respectively.
[0119] The term "alkylamino", as used herein, refers to an amino
group substituted with at least one alkyl group.
[0120] The term "alkylthio", as used herein, refers to a thiol
group substituted with an alkyl group and may be represented by the
general formula alkyl-S--.
[0121] The term "alkynyl", as used herein, refers to an aliphatic
group containing at least one triple bond and is intended to
include both "unsubstituted alkynyls" and "substituted alkynyls",
the latter of which refers to alkynyl moieties having substituents
replacing a hydrogen on one or more carbons of the alkynyl group.
Such substituents may occur on one or more carbons that are
included or not included in one or more triple bonds. Moreover,
such substituents include all those contemplated for alkyl groups,
as discussed above, except where stability is prohibitive. For
example, substitution of alkynyl groups by one or more alkyl,
cycloalkyl, heterocyclyl, aryl, or heteroaryl groups is
contemplated.
[0122] The term "amide" or "amido", as used herein, refers to a
group
##STR00012##
wherein R.sup.x and R.sup.y each independently represent a hydrogen
or hydrocarbyl group, or R.sup.x and R.sup.y taken together with
the N atom to which they are attached complete a heterocycle having
from 4 to 8 atoms in the ring structure.
[0123] The terms "amine" and "amino" are art-recognized and refer
to both unsubstituted and substituted amines and salts thereof,
e.g., a moiety that can be represented by
##STR00013##
wherein R.sup.x, R.sup.y, and R.sup.z each independently represent
a hydrogen or a hydrocarbyl group, or R.sup.x and R.sup.y taken
together with the N atom to which they are attached complete a
heterocycle having from 4 to 8 atoms in the ring structure.
[0124] The term "aminoalkyl", as used herein, refers to an alkyl
group substituted with an amino group.
[0125] The term "aralkyl", as used herein, refers to an alkyl group
substituted with an aryl group.
[0126] The term "aryl" as used herein includes substituted or
unsubstituted single-ring aromatic groups in which each atom of the
ring is carbon. In certain embodiments, the ring is a 5- to
7-membered ring, and in more specific embodiments is a 6-membered
ring. The term "aryl" also includes polycyclic ring systems having
two or more cyclic rings in which two or more carbons are common to
two adjoining rings wherein at least one of the rings is aromatic,
e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls,
cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl
groups include benzene, naphthalene, phenanthrene, phenol, aniline,
and the like.
[0127] The term "carbamate" is art-recognized and refers to a
group
##STR00014##
wherein R.sup.x and R.sup.y independently represent hydrogen or a
hydrocarbyl group, or R.sup.x and R.sup.y taken together with the
atoms to which they are attached complete a heterocycle having from
4 to 8 atoms in the ring structure.
[0128] The term "cycloalkyl", as used herein, refers to a
non-aromatic saturated or unsaturated ring in which each atom of
the ring is carbon. In certain embodiments, a cycloalkyl ring
contains from 3 to 10 atoms, and in more specific embodiments from
5 to 7 atoms.
[0129] The term "carbonate" is art-recognized and refers to a group
--OCO.sub.2--R.sup.x, wherein R.sup.x represents a hydrocarbyl
group.
[0130] The term "carboxy", as used herein, refers to a group
represented by the formula --CO.sub.2H.
[0131] The term "ester", as used herein, refers to a group
--C(O)OR.sup.x wherein R.sup.x represents a hydrocarbyl group.
[0132] The term "ether", as used herein, refers to a hydrocarbyl
group linked through an oxygen to another hydrocarbyl group.
Accordingly, an ether substituent of a hydrocarbyl group may be
hydrocarbyl-O--. Ethers may be either symmetrical or unsymmetrical.
Examples of ethers include, but are not limited to,
heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include
"alkoxyalkyl" groups, which may be represented by the general
formula alkyl-O-alkyl.
[0133] The term "guanidinyl" is art-recognized and may be
represented by the general formula
##STR00015##
wherein R.sup.x and R.sup.y independently represent hydrogen or a
hydrocarbyl.
[0134] The terms "halo" and "halogen" as used herein mean halogen
and include chloro, fluoro, bromo, and iodo.
[0135] The terms "hetaralkyl" and "heteroaralkyl", as used herein,
refer to an alkyl group substituted with a hetaryl group.
[0136] The terms "heteroaryl" and "hetaryl" include substituted or
unsubstituted aromatic single ring structures, in certain specific
embodiments 5- to 7-membered rings, more specifically 5- to
6-membered rings, whose ring structures include at least one
heteroatom, in some embodiments one to four heteroatoms, and in
more specific embodiments one or two heteroatoms. The terms
"heteroaryl" and "hetaryl" also include polycyclic ring systems
having two or more cyclic rings in which two or more carbons are
common to two adjoining rings wherein at least one of the rings is
heteroaromatic, e.g., the other cyclic rings can be cycloalkyls,
cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or
heterocyclyls. Heteroaryl groups include, for example, pyrrole,
furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine,
pyrazine, pyridazine, and pyrimidine, and the like.
[0137] The term "heteroatom" as used herein means an atom of any
element other than carbon or hydrogen. Typical heteroatoms are
nitrogen, oxygen, and sulfur.
[0138] The terms "heterocyclyl", "heterocycle", and "heterocyclic"
refer to substituted or unsubstituted non-aromatic ring structures,
in certain specific embodiments 3- to 10-membered rings, more
specifically 3- to 7-membered rings, whose ring structures include
at least one heteroatom, in some embodiments one to four
heteroatoms, and in more specific embodiments one or two
heteroatoms. The terms "heterocyclyl" and "heterocyclic" also
include polycyclic ring systems having two or more cyclic rings in
which two or more carbons are common to two adjoining rings wherein
at least one of the rings is heterocyclic, e.g., the other cyclic
rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls,
heteroaryls, and/or heterocyclyls. Heterocyclyl groups include, for
example, piperidine, piperazine, pyrrolidine, morpholine, lactones,
lactams, and the like.
[0139] The term "heterocyclylalkyl", as used herein, refers to an
alkyl group substituted with a heterocycle group.
[0140] The term "hydrocarbyl", as used herein, refers to a group
that is bonded through a carbon atom that does not have a .dbd.O or
.dbd.S substituent, and typically has at least one carbon-hydrogen
bond and a primarily carbon backbone, but may optionally include
heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and
trifluoromethyl are considered to be hydrocarbyl for the purposes
herein, but substituents such as acetyl (which has a .dbd.O
substituent on the linking carbon) and ethoxy (which is linked
through oxygen, not carbon) are not. Hydrocarbyl groups include,
but are not limited to aryl, heteroaryl, carbocycle, heterocycle,
alkyl, alkenyl, alkynyl, and combinations thereof.
[0141] The term "hydroxyalkyl", as used herein, refers to an alkyl
group substituted with a hydroxy group.
[0142] The term "lower" when used in conjunction with a chemical
moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy
is meant to include groups where there are ten or fewer
non-hydrogen atoms in the substituent, and in certain embodiments,
six or fewer. A "lower alkyl", for example, refers to an alkyl
group that contains ten or fewer carbon atoms, and in specific
embodiments six or fewer carbon atoms. In certain embodiments, the
acyl, acyloxy, alkyl, alkenyl, alkynyl, and alkoxy substituents
defined herein are respectively lower acyl, lower acyloxy, lower
alkyl, lower alkenyl, lower alkynyl, and lower alkoxy, whether they
appear alone or in combination with other substituents, such as in
the recitations hydroxyalkyl and aralkyl (in which case, for
example, the atoms within the aryl group are not counted when
counting the carbon atoms in the alkyl substituent).
[0143] The terms "polycyclyl", "polycycle", and "polycyclic" refer
to two or more rings (e.g., cycloalkyls, cycloalkenyls,
cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which
two or more atoms are common to two adjoining rings, e.g., the
rings are "fused rings". Each of the rings of the polycycle can be
substituted or unsubstituted. In certain embodiments, each ring of
the polycycle contains from 3 to 10 atoms in the ring, more
specifically from 5 to 7.
[0144] The term "substituted" refers to moieties having
substituents replacing a hydrogen on one or more carbons of the
backbone. It will be understood that "substitution" or "substituted
with" includes the implicit proviso that such substitution is in
accordance with permitted valence of the substituted atom and the
substituent, and that the substitution results in a stable
compound, e.g., a compound that does not spontaneously undergo
transformation such as by rearrangement, cyclization, elimination,
etc., under conditions in which the compound is to be used. As used
herein, the term "substituted" is contemplated to include all
permissible substituents of organic compounds. In a broad aspect,
the permissible substituents include acyclic and cyclic, branched
and unbranched, carbocyclic and heterocyclic, aromatic and
non-aromatic substituents of organic compounds. The permissible
substituents can be one or more and the same or different for
appropriate organic compounds. For purposes of this invention, the
heteroatoms such as nitrogen may have hydrogen substituents and/or
any permissible substituents of organic compounds described herein
which satisfy the valences of the heteroatoms. Substituents may
include any substituents described herein, for example, a halogen,
a hydroxyl, a carbonyl (such as a keto, a carboxy, an
alkoxycarbonyl, a formyl, an acyl, a carbonate, a carbamate, an
ester, or a urea), a thiocarbonyl (such as a thioester, a
thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a
phosphate, a phosphonate, a phosphinate, an amino, an amido, an
amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an
alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a
sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or
heteroaromatic moiety. It will be understood by those skilled in
the art that the moieties substituted on the hydrocarbon chain may
themselves be substituted, if appropriate.
[0145] Unless specifically described as "unsubstituted", references
to chemical moieties herein are understood to include substituted
variants. For example, reference to an "aryl" group or moiety
implicitly includes both substituted and unsubstituted
variants.
[0146] The term "sulfate" is art-recognized and refers to the group
--OSO.sub.3H, or a pharmaceutically acceptable salt thereof.
[0147] The term "sulfonamide" is art-recognized and refers to the
group represented by the general formulae
##STR00016##
wherein R.sup.x and R.sup.y independently represent hydrogen or
hydrocarbyl.
[0148] The term "sulfoxide" is art-recognized and refers to the
group --S(O)--R.sup.x, wherein R.sup.x represents a
hydrocarbyl.
[0149] The term "sulfonate" is art-recognized and refers to the
group --SO.sub.3H, or a pharmaceutically acceptable salt
thereof.
[0150] The term "sulfone" is art-recognized and refers to the group
--S(O).sub.2--R.sup.x, wherein R.sup.x represents a
hydrocarbyl.
[0151] The term "thioalkyl", as used herein, refers to an alkyl
group substituted with a thiol group.
[0152] The term "thioester", as used herein, refers to a group
--C(O)SR.sup.x or --SC(O)R.sup.x wherein R.sup.x represents a
hydrocarbyl.
[0153] The term "thioether", as used herein, is equivalent to an
ether, wherein the oxygen is replaced with a sulfur.
[0154] The term "urea" is art-recognized and may be represented by
the general formula
##STR00017##
wherein R.sup.x and R.sup.y independently represent hydrogen or a
hydrocarbyl.
[0155] It should be understood that some of the compounds of the
invention may contain one or more stereocenters, and that, absent
an explicit indication otherwise, compounds containing only one or
the other stereoisomer at the stereocenter, or a mixture of the
stereoisomers, in any combination, are considered within the scope
of the invention. For example, the compounds of the invention may
be pure enantiomeric or diastereomeric forms of a given molecule or
may be mixtures of the enantiomeric or diastereomic forms, at any
ratio.
[0156] In some embodiments of the above category of compounds,
R.sub.i2 is a phenyl group optionally substituted with one or more
alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido groups. In specific
embodiments, R.sub.i2 is a phenyl group optionally substituted with
one or more alkyl, alkoxy, or halo groups.
[0157] In some embodiments, R.sub.e is an optionally substituted
C.sub.3-C.sub.8-alkyl or aralkyl group, or R.sub.e is an optionally
substituted C.sub.3-C.sub.8-alkyl group.
[0158] In some embodiments, R.sub.p1 and R.sub.p2 are independently
H, alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido. In specific
embodiments, R.sub.p1 and R.sub.p2 are independently H, alkyl,
alkoxy, or halo.
[0159] A second category of compounds is represented by structural
formula (II), or a pharmaceutically acceptable salt thereof,
wherein:
[0160] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0161] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0162] R.sub.i2 is a phenyl group substituted with one or more
alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio,
aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring;
[0163] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0164] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0165] provided that R.sub.i2 is not 2-aminophenyl, 3-aminophenyl,
3-amino-4-hydroxyphenyl, 4-aminophenyl, 3-azidophenyl,
1,1'-biphenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-carboxyphenyl, 2-(chlorocarbonyl)phenyl, 4-chlorophenyl,
2,4-dichlorophenyl, 2,4-dimethoxyphenyl, 3,4-dimethoxyphenyl,
3,4-dimethylphenyl, 4-fluorophenyl, 2-methoxyphenyl,
3-methoxyphenyl, 4-methoxyphenyl, 3-(ethoxycarbonyl)phenyl,
4-(methoxycarbonyl)phenyl, 2-methylphenyl, 4-methylphenyl,
4-(methylsulfonyl)phenyl, 4-(methylthio)phenyl,
3-(4-morpholinylsulfonyl)phenyl, 2-nitrophenyl, 3-nitrophenyl,
4-nitrophenyl, 3-(phenylamino)phenyl, 4-(1H-pyrrol-1-yl)phenyl,
4-(1-methyl-1H-pyrazol-4-yl)phenyl, 2-hydroxy-5-aminophenyl, or
4-[5-(4-chlorophenyl)-3-(ethoxycarbonyl)-2-methyl-1H-pyrrol-1-yl]phenyl].
[0166] In more specific embodiments of this category, R.sub.i2 is a
phenyl group substituted with one or more alkyl, alkoxy, hydroxyl,
thio, amino, carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido groups. Even more specifically, R.sub.i2 is a phenyl group
substituted with one or more alkyl, alkoxy, or halo groups.
[0167] In other more specific embodiments, R.sub.e is an optionally
substituted lower alkyl or aralkyl group or R.sub.e is an
optionally substituted lower alkyl group.
[0168] In still other more specific embodiments, R.sub.p1 and
R.sub.p2 are independently H, alkyl, alkoxy, hydroxyl, thio, amino,
carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido, or R.sub.p1 and R.sub.p2 are independently H, alkyl, alkoxy,
or halo.
[0169] A third category of compounds is represented by structural
formula (IV):
##STR00018##
or a pharmaceutically acceptable salt thereof, wherein:
[0170] R.sub.p3 and R.sub.p4 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0171] R.sub.i1 is H or a C.sub.1-C.sub.6 alkyl group;
[0172] R.sub.i5 is a phenyl group substituted with one or more
alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido groups;
[0173] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0174] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0175] provided that R.sub.i5 is not 2-aminophenyl, 2-bromophenyl,
2-carboxyphenyl, 2-chlorophenyl, 2-(dimethylamino)phenyl,
2-ethylphenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 2-methylphenyl,
2-nitrophenyl, 2-trifluoromethylphenyl, 3-acetylphenyl,
3-aminophenyl, 3-aminocarbonylphenyl, 3-azidophenyl, 3-bromophenyl,
3-butoxyphenyl, 3-carboxyphenyl, 3-chlorophenyl,
3-(dimethylamino)phenyl, 3-fluorophenyl, 3-hydroxylphenyl,
3-iodophenyl, 3-methoxyphenyl, 3-methylphenyl, 3-methylthiophenyl,
3-nitrophenyl, 3-trifluoromethylphenyl, 4-aminophenyl,
4-azidophenyl, 4-bromophenyl, 4-carboxyphenyl, 4-chlorophenyl,
4-ethoxyphenyl, 4-ethylphenyl, 4-fluorophenyl, 4-hydroxyphenyl,
4-methoxyphenyl, 4-methylphenyl, 4-nitrophenyl,
4-trifluoromethoxyphenyl, 4-(3,3,3-trifluoropropoxy)phenyl,
2,4-difluorophenyl, 2,4-dichlorophenyl, 3-amino-4-hydroxyphenyl,
3-carboxy-4-hydroxyphenyl, 2-hydroxy-5-aminophenyl,
2-bromo-4-acetylphenyl, 2,4-dibromophenyl,
2-bromo-4-(ethoxycarbonyl)phenyl, 2-bromo-4-fluorophenyl,
2-bromo-4-trifluoromethylphenyl, 3-hydroxy-4-carboxyphenyl,
3-carboxy-4-hydroxyphenyl, 2,6-diisopropylphenyl,
2,5-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,3-dimethylphenyl,
2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl,
3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-methoxy-4-methylphenyl,
2-methyl-3-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl,
3,5-dichlorophenyl, 2-methoxy-5-nitrophenyl,
2-nitro-4-methylphenyl, or 2-chloro-5-trifluoromethylphenyl.
[0176] In more specific embodiments of this category, R.sub.i5 is a
phenyl group optionally substituted with one or more alkyl, alkoxy,
or halo groups.
[0177] In other more specific embodiments, R.sub.e is an optionally
substituted lower alkyl or aralkyl group, or R.sub.e is an
optionally substituted lower alkyl group.
[0178] In still other more specific embodiments, R.sub.p3 and
R.sub.p4 are independently H, alkyl, alkoxy, hydroxyl, thio, amino,
carboxy, carbonate, carbamate, guanidinyl, urea, halo,
trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or
azido. Even more specifically, R.sub.p3 and R.sub.p4 are
independently H, alkyl, alkoxy, or halo.
[0179] A fourth category of compounds is represented by structural
formula (II):
##STR00019##
or a pharmaceutically acceptable salt thereof, wherein:
[0180] R.sub.p1 and R.sub.p2 are independently H, alkyl, alkenyl,
alkynyl, alkoxy, alkanoyl, alkylamino, cycloalkyl, cycloalkenyl,
cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, alkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or
azido, each of which may be optionally substituted where chemically
feasible;
[0181] R.sub.i1 is H;
[0182] R.sub.i2 is a phenyl group optionally substituted with one
or more alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino,
alkylthio, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl,
aralkamino, heteroaryl, heteroaryloxy, heteroarylamino,
heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl,
cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino,
heterocyclylalky, heterocyclylalkoxy, heterocyclylalkanoyl,
heterocyclylalkamino, hydroxyl, thio, amino, amido, alkanoylamino,
aroylamino, aralkanoylamino, alkylcarboxy, alkylcarbonyl,
aminocarbonyl, alkylaminocarbonyl, carboxy, carbonate, carbamate,
guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl,
sulfonyl, sulfonamido, or azido groups, and wherein two adjacent
substituent groups can combine to form a ring;
[0183] R.sub.i3 is H or an unsubstituted lower alkyl group; and
[0184] R.sub.e is alkyl, alkenyl, alkynyl, aryl, aralkyl,
heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocyclyl,
or heterocyclylalky, and is optionally substituted with alkyl,
alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylthio, aryl,
aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino,
heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl,
heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl,
cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino,
heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino,
hydroxyl, thio, amino, amido, alkanoylamino, aroylamino,
aralkanoylamino, alkylcarboxy, alkylcarbonyl, aminocarbonyl,
alkylaminocarbonyl, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, or azido;
[0185] provided that
[0186] when R.sub.i2 is 4-(methylsulfonyl)phenyl, R.sub.e is
methyl, and R.sub.p1 is H, then R.sub.p2 is not 4-fluoro; and
[0187] when R.sub.i2 is unsubstituted phenyl, R.sub.e is methyl,
and R.sub.p1 is H, then R.sub.p2 is not 4-methoxy.
[0188] In more specific embodiments of this category, R.sub.i2 is a
phenyl group optionally substituted with one or more alkyl, alkoxy,
hydroxyl, thio, amino, carboxy, carbonate, carbamate, guanidinyl,
urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl,
sulfonamido, or azido groups.
[0189] In still more specific embodiments, R.sub.i2 is a phenyl
group optionally substituted with one or more alkyl, alkoxy, or
halo groups.
[0190] In some embodiments, R.sub.e is an optionally substituted
lower alkyl or aralkyl group or is an optionally substituted lower
alkyl group.
[0191] In some embodiments, R.sub.p1 and R.sub.p2 are independently
H, alkyl, alkoxy, hydroxyl, thio, amino, carboxy, carbonate,
carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro,
phosphoryl, sulfonyl, sulfonamido, or azido.
[0192] In specific embodiments, R.sub.p1 and R.sub.p2 are
independently H, alkyl, alkoxy, or halo.
Pharmaceutical Compositions
[0193] In another aspect, the instant invention provides
pharmaceutical compositions comprising a compound of the invention
and a pharmaceutically acceptable carrier.
[0194] Pharmaceutically acceptable carriers are well known in the
art and include, for example, aqueous solutions such as water or
physiologically buffered saline or other solvents or vehicles such
as glycols, glycerol, oils such as olive oil, injectable organic
esters, lipid emulsions such as intralipid and the like, and other
suitable carriers. In a specific embodiment, when such
pharmaceutical compositions are for human administration, the
aqueous solution is pyrogen free, or substantially pyrogen free.
The excipients may be chosen, for example, to effect delayed
release of an agent or to selectively target one or more cells,
tissues or organs. The pharmaceutical composition may be in dosage
unit form such as tablet, capsule, sprinkle capsule, granule,
powder, syrup, suppository, injection or the like. The composition
may also be present in a transdermal delivery system, e.g., a skin
patch.
[0195] A pharmaceutically acceptable carrier may contain
physiologically acceptable agents that act, for example, to
stabilize or to increase the absorption of a compound of the
instant invention. Such physiologically acceptable agents include,
for example, carbohydrates, such as glucose, sucrose or dextrans,
antioxidants, such as ascorbic acid or glutathione, chelating
agents, low molecular weight proteins or other stabilizers or
excipients. The choice of a pharmaceutically acceptable carrier,
including a physiologically acceptable agent, depends, for example,
on the route of administration of the composition. The
pharmaceutical composition also may comprise a liposome or other
polymer matrix, which may have incorporated therein, for example, a
compound of the invention. Liposomes, for example, which consist of
phospholipids or other lipids, are nontoxic, physiologically
acceptable and metabolizable carriers that are relatively simple to
make and administer.
[0196] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions, and/or dosage
forms that are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0197] The phrase "pharmaceutically acceptable carrier" as used
herein means a pharmaceutically acceptable material, composition,
or vehicle, such as a liquid or solid filler, diluent, excipient,
solvent, or encapsulating material, involved in carrying or
transporting the subject compounds from one organ, or portion of
the body, to another organ, or portion of the body. Each carrier
must be "acceptable" in the sense of being compatible with the
other ingredients of the formulation and not injurious to the
patient. Some examples of materials that can serve as
pharmaceutically acceptable carriers include: (1) sugars, such as
lactose, glucose and sucrose; (2) starches, such as corn starch and
potato starch; (3) cellulose, and its derivatives, such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4)
powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8)
excipients, such as cocoa butter and suppository waxes; (9) oils,
such as peanut oil, cottonseed oil, safflower oil, sesame oil,
olive oil, corn oil and soybean oil; (10) glycols, such as
propylene glycol; (11) polyols, such as glycerin, sorbitol,
mannitol and polyethylene glycol; (12) esters, such as ethyl oleate
and ethyl laurate; (13) agar; (14) buffering agents, such as
magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)
pyrogen-free water; (17) isotonic saline; (18) Ringer's solution;
(19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other
non-toxic compatible substances employed in pharmaceutical
formulations. See Remington: The Science and Practice of Pharmacy,
20th ed. (Alfonso R. Gennaro ed.), 2000.
[0198] A pharmaceutical composition containing a compound of the
instant invention may be administered to a subject by any of a
number of routes of administration including, for example, orally
(for example, drenches as in aqueous or non-aqueous solutions or
suspensions, tablets, boluses, powders, granules, pastes for
application to the tongue); sublingually; anally, rectally, or
vaginally (for example, as a pessary, cream, or foam); parenterally
(including intramuscularly, intravenously, subcutaneously, or
intrathecally as, for example, a sterile solution or suspension);
nasally; intraperitoneally; subcutaneously; transdermally (for
example as a patch applied to the skin); or topically (for example,
as a cream, ointment or spray applied to the skin). The compound
may also be formulated for inhalation. In certain embodiments, a
compound of the instant invention may be simply dissolved or
suspended in sterile water. Details of appropriate routes of
administration and compositions suitable for same can be found in,
for example, U.S. Pat. Nos. 6,110,973; 5,763,493; 5,731,000;
5,541,231; 5,427,798; 5,358,970; and 4,172,896, as well as in
patents cited therein.
[0199] The formulations of the present invention may conveniently
be presented in unit dosage form and may be prepared by any methods
well known in the art of pharmacy. The amount of active ingredient
that may be combined with a carrier material to produce a single
dosage form will vary depending upon the subject being treated and
the particular mode of administration. The amount of active
ingredient that may be combined with a carrier material to produce
a single dosage form will generally be that amount of the compound
that produces a therapeutic effect. Generally, out of one hundred
percent, this amount will range from about 0.1 percent to about 50
percent of active ingredient, in some embodiments from about 0.2
percent to about 10 percent, and in more specific embodiments from
about 0.5 percent to about 2 percent. For example, compounds of the
present disclosure may be formulated in a unit dose form between
about 1 .mu.g and 1000 mg. In some embodiments, compounds or
compositions of the present disclosure may be formulated in a unit
dose of about 1 .mu.g to 20 .mu.g, of about 20 .mu.g to 1 mg, of
about 1 mg to 10 mg, of about 10 mg to 100 mg, and of about 50 mg
to 500 mg. In particular, an embodiment including a compound may be
formulated in 0.1 .mu.g, 0.2 .mu.g, 0.5 .mu.g, 1 .mu.g, 20 .mu.g,
50 .mu.g, 100 .mu.g, 200 .mu.g, 500 .mu.g, 1 mg, 2 mg, 5 mg, 10 mg,
20 mg, 50 mg, 100 mg, 200 mg, and 500 mg unit dose form.
[0200] Formulations of the invention suitable for oral
administration may be in the form of capsules, cachets, pills,
tablets, lozenges (using a flavored basis, usually sucrose and
acacia or tragacanth), powders, granules, or as a solution or a
suspension in an aqueous or non-aqueous liquid, or as an
oil-in-water or water-in-oil liquid emulsion, or as an elixir or
syrup, or as pastilles (using an inert base, such as gelatin and
glycerin, or sucrose and acacia) and/or as mouth washes and the
like, each containing a predetermined amount of a compound of the
present invention as an active ingredient. A compound of the
present invention may also be administered as a bolus, electuary,
or paste.
[0201] In solid dosage forms of the invention for oral
administration (capsules, tablets, pills, dragees, powders,
granules and the like), the active ingredient is mixed with one or
more pharmaceutically acceptable carriers, such as sodium citrate
or dicalcium phosphate, and/or any of the following: (1) fillers or
extenders, such as starches, lactose, sucrose, glucose, mannitol,
and/or silicic acid; (2) binders, such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone,
sucrose and/or acacia; (3) humectants, such as glycerol; (4)
disintegrating agents, such as agar-agar, calcium carbonate, potato
or tapioca starch, alginic acid, certain silicates, and sodium
carbonate; (5) solution retarding agents, such as paraffin; (6)
absorption accelerators, such as quaternary ammonium compounds; (7)
wetting agents, such as, for example, cetyl alcohol and glycerol
monostearate; (8) absorbents, such as kaolin and bentonite clay;
(9) lubricants, such a talc, calcium stearate, magnesium stearate,
solid polyethylene glycols, sodium lauryl sulfate, and mixtures
thereof; and (10) coloring agents. In the case of capsules, tablets
and pills, the pharmaceutical compositions may also comprise
buffering agents. Solid compositions of a similar type may also be
employed as fillers in soft and hard-filled gelatin capsules using
such excipients as lactose or milk sugars, as well as high
molecular weight polyethylene glycols and the like.
[0202] The tablets, and other solid dosage forms of the
pharmaceutical compositions of the present invention, such as
dragees, capsules, pills and granules, may optionally be scored or
prepared with coatings and shells, such as enteric coatings and
other coatings well known in the pharmaceutical-formulating art.
They may also be formulated so as to provide slow or controlled
release of the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the
desired release profile, other polymer matrices, liposomes and/or
microspheres. They may be sterilized by, for example, filtration
through a bacteria-retaining filter, or by incorporating
sterilizing agents in the form of sterile solid compositions that
can be dissolved in sterile water, or some other sterile injectable
medium immediately before use. These compositions may also
optionally contain opacifying agents and may be of a composition
that they release the active ingredient(s) only, or preferentially,
in a certain portion of the gastrointestinal tract, optionally, in
a delayed manner. Examples of embedding compositions that may be
used include polymeric substances and waxes. The active ingredient
may also be in micro-encapsulated form, if appropriate, with one or
more of the above-described excipients.
[0203] Liquid dosage forms for oral administration of the compounds
of the invention include pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active ingredient, the liquid dosage forms may
contain inert diluents commonly used in the art, such as, for
example, water or other solvents, solubilizing agents and
emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, oils (in particular,
cottonseed, groundnut, corn, germ, olive, castor and sesame oils),
glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty
acid esters of sorbitan, and mixtures thereof.
[0204] Besides inert diluents, the oral compositions may also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring, coloring, perfuming, and
preservative agents.
[0205] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular,
subarachnoid, intraspinal, and intrasternal injection and
infusion.
[0206] Pharmaceutical compositions of this invention suitable for
parenteral administration comprise one or more compounds of the
invention in combination with one or more pharmaceutically
acceptable sterile isotonic aqueous or nonaqueous solutions,
dispersions, suspensions, or emulsions, or sterile powders which
may be reconstituted into sterile injectable solutions or
dispersions just prior to use, which may contain antioxidants,
buffers, bacteriostats, solutes which render the formulation
isotonic with the blood of the intended recipient or suspending or
thickening agents.
[0207] Examples of suitable aqueous and nonaqueous carriers that
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, injectable organic
esters, such as ethyl oleate, and lipid emulsions, such as
Intralipid and the like. Proper fluidity may be maintained, for
example, by the use of coating materials, such as lecithin, by the
maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0208] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents, and dispersing
agents. Prevention of the action of microorganisms may be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid, chelators
and the like. It may also be desirable to include isotonic agents,
such as sugars, sodium chloride, and the like into the
compositions. In addition, prolonged absorption of the injectable
pharmaceutical form may be brought about by the inclusion of agents
that delay absorption such as aluminum monostearate and
gelatin.
[0209] In some cases, in order to prolong the effect of a drug, it
is desirable to slow the absorption of the drug from subcutaneous
or intramuscular injection. This may be accomplished by the use of
a liquid suspension of crystalline or amorphous material having
poor water solubility. The rate of absorption of the drug then
depends upon its rate of dissolution, which, in turn, may depend
upon crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0210] Injectable depot forms are made by forming microencapsuled
matrices of the subject compounds in biodegradable polymers such as
polylactide-polyglycolide. Depending on the ratio of drug to
polymer, and the nature of the particular polymer employed, the
rate of drug release may be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions that are
compatible with body tissue.
[0211] Methods of introduction may also be provided by rechargeable
or biodegradable devices. Various slow release polymeric devices
have been developed and tested in vivo in recent years for the
controlled delivery of drugs. A variety of biocompatible polymers
(including hydrogels), including both biodegradable and
non-degradable polymers, may be used to form an implant for the
sustained release of a compound at a particular target site.
[0212] Anesthetic compounds, including the compounds of the instant
disclosure, often display limited solubility in aqueous solution,
and they are therefore preferably formulated with one or more
agents that increase their solubility in water. Examples of such
agents include surfactants and lipid emulsions, or other similar
solubilizing agents, and the compositions may include one or more
additional solvents. Alternatively, the compositions may include an
additional water-miscible, non-aqueous solvent, provided in
sufficient concentration in the aqueous solution to obtain a
homogeneous composition. In yet another alternative, the
compositions may include an oil-in-water emulsion in which the
instant anesthetic compound, either alone or dissolved in a
water-immiscible solvent, for example, an oil, is emulsified with
water by means of a surfactant. Suitable surfactants and other
solubilizing agents are well known in the art, for example, the
surfactants described for use in formulating propofol and
etomidate. See, e.g., U.S. Pat. Nos. 4,056,635; 4,289,783;
4,798,846; 5,731,355; 5,858,410; 7,915,317; 8,383,687; 8,796,340,
the disclosures of which are hereby incorporated by reference
herein in their entireties. Such agents include without limitation,
oils, lipids, polyols, and the like, in any combination and ratio.
As noted above, the formulations optionally contain additional
agents, such as anti-microbial agents and the like.
[0213] In another aspect, the invention is provided substantially
as described in any part of the instant disclosure, including the
examples, in any combination, and as shown in the accompanying
drawings.
[0214] It will be readily apparent to one of ordinary skill in the
relevant arts that other suitable modifications and adaptations to
the methods and applications described herein may be made without
departing from the scope of the invention or any embodiment
thereof. Having now described the present invention in detail, the
same will be more clearly understood by reference to the following
Examples, which are included herewith for purposes of illustration
only and are not intended to be limiting of the invention.
Examples
Molecular Modeling and Testing of Compounds as Novel Anesthetic
Agents
Materials and Methods:
[0215] 1. Homologous Template Identification and Analyses
[0216] The cryo-electron microscopy-derived structure of the alpha
1 subunit from the torpedo nicotinic acetylcholine receptor (nAChR,
PDB ID 2BG9) (Unwin (2005) J Mol Biol 346:967-89), the NMR derived,
transmembrane domain structures of the alpha 4 and beta 2 subunits
of the nAChR (PDB ID 2LLY, 2LM2) (Bondarenko et al. (2012) Biochim
Biophys Acta 1818:1261-8), and the crystallographically derived
structures of the eukaryotic glutamate-gated chloride channel
(GluCl, PDB ID 3RIF, 3RHW) (Hibbs et al. (2011) Nature 474:54-60),
as well as the prokaryotic pH sensing channels, Gloeobacter
violaceus ion channel (GLIC, PDB ID 3EAM) (Corringer et al. (2009)
J Physiol 588:565-72; Bocquet et al. (2009) Nature 457:111-4), and
Erwinia chrysanthemi ion channel (ELIC, PDB ID 2VL0) (Hilf et al.
(2008) Nature 452:375-9) were downloaded from the Research
Collaboratory for Structural Biology (RCSB) protein databank. Most
of the calculations below were performed with algorithms present
within the Discovery Studio 3.1 software suite (Accelrys, San
Diego, Calif.) except where noted. Multiple structure alignments
were separately performed via the SAlign (Braberg et al. (2012)
Bioinformatics 28:2072-3) and 3DMA algorithms. A multiple sequence
alignment profile was then derived from these structural
alignments. The sequences of the individual subunits for the mouse
GABAaR were downloaded from the National Center for Biotechnology
Institute (NCBI). They were concatenated and arranged in the
clockwise order (as viewed from the extracellular side of the
channel) gamma 2, alpha 1, beta 3, alpha 1, beta 3 in accordance
with knowledge in the art. See Trudell (2002) Biochim Biophys Acta
1565:91-6; Sigel et al. (2012) J Biol Chem 287:40224-31; Baur et
al. (2006) FEBS Lett 580:1616-20; Baumann et al. (2002) J Biol Chem
277:46020-5; Tretter (1997) J Neurosci 17:2728-37. These works
demonstrate the appropriate stoichiometry and arrangement of
subunit subtypes so as to satisfy a variety of mutational results
required for specific ligand binding in the extracellular domain of
the GABAaR. See Cromer et al. (2002) Trends Biochem Sci 27:280-7;
Baur et al. (2010) J Neurochem 115:1478-85. The sequences of the
mouse GABAaR alpha 1, beta 3 and gamma 2 subunits were then aligned
with the previously derived sequence of the known structural
template (GluCl) using the Align123 algorithm, a version of the
ClustalW routine. Higgins et al. (1996) Methods Enzymol
266:383-402.
[0217] 2. Model Construction using the Modeller Algorithm
[0218] The GluCl structural coordinates were utilized as the
template for homology modeling for the reasons reviewed in the
Discussion section below. For the GluCl template, the native
glutamate ligand, which was located in the intersubunit cleft
within the extracellular domain, and the ivermectin located in the
intersubunit cleft in the transmembrane domain, were removed. The
Modeller (Eswar et al. (2008) Methods Mol Biol 426:145-59)
algorithm was used for assignment of coordinates for aligned amino
acids. Modeller implements comparative protein structure modeling
by satisfaction of spatial restraints that are obtained from the
set of structural templates, thereby generating a probability
density function governing the way in which heavy atom coordinates
are assigned. Routines implemented within the Modeller framework
also allow the construction and optimization of loops of amino
acids for which no template coordinates can be assigned, and the
initial refinement of amino acid sidechains. Final rotamer search
optimization was performed using the ChiRotor routine within
Discovery Studio.
[0219] 3. Docking to an Anesthetic Binding Site and Quantifying the
Interaction.
[0220] As in the inventors' previous work (Bertaccini et al. (2010)
J Chem Inf Model 50:2248-55), the binding sites were identified by
the convergence of residues relevant to anesthetic modulation on a
common transmembrane intersubunit location in three dimensional
space. The volume of the initial binding site was very small due to
the aforementioned energy optimizations and the rotation of amino
acid sidechains into the binding site. Therefore, a single propofol
molecule was manually inserted into one of the two putative binding
sites between alpha and beta subunits within the model built using
Modeller. This propofol was optimized into position using molecular
mechanics with the CHARMm force field, followed by molecular
dynamics (Brooks et al. (2009) J Comput Chem 30:1545-614), while
allowing for sidechain flexibility with only backbone atoms fixed.
While the work of Mihic et al. has demonstrated that occupancy of
only one binding site is sufficient to enhance the homologous
glycine receptor's function (Roberts et al. (2006) J Biol Chem
281:3305-11), the work of Forman et al. (Forman et al. (2012) Curr
Opin Anaesthesiol 25:411-8; Forman et al. (2011) Can J Anaesth
58:191-205; Ruesch et al. (2012) Anesthesiology 116:47-55; Stewart
et al. (2013) Mol Pharmacol 83:1200-08) shows that propofol's
enhancing action in GABAaR requires occupancy of perhaps three
propofol sites. For the sake of computational simplicity here and
since both binding sites are identical in amino acid contribution
and location between alpha and beta subunits, only one
transmembrane binding site was chosen for docking examinations. The
CDocker algorithm (Wu et al. (2003) J Comput Chem 24:1549-62) was
then used to randomly dock a congeneric series of flexible propofol
derivatives, as well as propofol itself, into a rigid binding
pocket and score their best relative binding affinities for
correlation with known GABAaR potentiation EC50's. CDOCKER is an
implementation of a CHARMm molecular mechanics-based docking tool
using a rigid receptor. This method begins by generating a set of
10 ligand conformations using 1000 steps of high-temperature
(1000K) molecular dynamics with different random seeds and includes
electrostatic interactions. Random pose orientations of the
conformations were produced by translating the center of the ligand
to a specified location within a predefined sphere incorporating
the receptor site, and performing a series of random rotations. The
sphere in this case was chosen as a 7 angstrom radius from the
center of mass of the initial manually docked propofol pose. This
was done in an effort to both center the region of docking
exploration within the area of relevant residues as well as to have
a large enough radius to allow adequate random placement about
these residues. A softened (temporarily reduced van der Waals
radii) energy was calculated and the orientation kept if the energy
was less than a specified threshold (300 kcal/mol). This process
continued until either the desired number of low-energy
orientations was found (set at 10), or the maximum number of bad
orientations were tried (set at 800). Each orientation was
subjected to simulated annealing molecular dynamics. The
temperature was heated to a high enough level (700K over 2000
steps) to overcome local energy barriers between adjacent minima
and then cooled to the target temperature (300K over 5000 steps). A
final minimization of the ligand in the rigid receptor using a
non-softened full potential (including full van der Waals radii and
electrostatics) was performed. For each final pose, the CDOCKER
score energy (interaction energy plus ligand strain) and the
CDOCKER interaction score alone were calculated. The poses were
sorted and the top scoring (most negative, thus favorable to
binding) poses were retained. For performance, many of these steps
used a nonbonded energy grid, rather than the full potential energy
terms usually used by CHARMm. This choice can provide a significant
time saving during large database screening, but was reverted to
its fully explicit CHARMm form during final optimizations to avoid
the loss of some initial accuracy associated with the initial
grid-based search.
[0221] The compounds with agonist activity that were docked
included propofol (2,6-diisopropylphenol); 2,6-dimethylphenol;
phenol; 2,6-diethylphenol; 2-isopropylphenol; 2,6-disecbutylphenol.
This is the same series of propofol analogs studied by Eckenhoff
and colleagues for their correlation of binding free energy to
horse spleen apoferritin derived from isothermal titration
calorimetry with experimentally derived EC50 for GABAaR
potentiation. Vedula et al. (2009) J Biol Chem 284:24176-84;
Krasowski et al. (2001) J Pharmacol Exp Ther 297:338-51. These
compounds were specifically chosen for the instant docking studies
as they are the only propofol derivatives which also have
experimentally derived specific binding constants to horse spleen
apoferritin. It is the latter which were initially and reliably
reproduced with the CDocker methodologies as a means of method
validation specific to this set of compounds (unpublished data).
Finally, as inactive controls, both the cis and trans forms of the
nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6), were docked
to the same binding site. This compound is without known potency
for response to a painful stimulus (hence the name, nonimmobilizer)
and is experimentally devoid of activity at the GABAaR. Mihic et
al. (1994) Mol Pharmacol 46:851-7. As additional controls, the
following propofol analogs, noted for their inactivity at the
GABAaR (Krasowski et al. (2001) J Pharmacol Exp Ther 297:338-51),
were docked: dicyclohexylphenol, ditert-2,6-butylphenol,
cyclopentylphenol and dicyclopentylphenol. Linear regression
analysis correlating the best negative CDocker score of each
compound with the negative logarithm of its experimentally derived
GABAaR EC50 for potentiation was performed within Microsoft Excel
2007 (Microsoft Inc., Redmond, Wash.).
[0222] With docking validation derived from the aforementioned
calculations, a new set of in silico molecular docking calculations
was performed using the series of known etomidate-like derivatives
described by Biggio et al. See Asproni et al. (2005) J Med Chem
48:2638-45. The most potent agent for GABAaR potentiation within
this series is TG41. See FIG. 1A and Mascia et al. (2005) Eur J
Pharmacol 516:204-11. However, since these compounds contain an
unbonded imidazole nitrogen, which is likely to inhibit 11-beta
hydroxylase corticosteroid biosynthesis (see below), and as has
been known to occur with etomidate, the structure of the most
potent version of this series was modified to a completely new
compound. See FIG. 1B. For comparison, a carbo version of etomidate
has recently been shown to display lower inhibition of
adrenocortical steroid biosynthesis. See, Shanmugasundararaj et al.
(2013) Anesth Analg 116:1249-56, and U.S. Pat. No. 8,765,973.
[0223] The Chemical Abstracts Database was searched for other
structures with at least 80% similarity to carbo-1n for purposes of
in silico docking and in vitro and in vivo testing. The structures
of the selected compounds are displayed in Table 1:
TABLE-US-00001 TABLE 1 Structures of compounds identified by in
silico modeling based on similarity to carbo 1n. Cpd. Structure A
##STR00020## B ##STR00021## C ##STR00022## D ##STR00023## E
##STR00024## F ##STR00025## G ##STR00026## H ##STR00027## J
##STR00028## K ##STR00029## L ##STR00030## M ##STR00031##
[0224] The receptor binding site for this series was created by
using the previously formed propofol docking site and allowing
residues within a 5 angstrom radius of the docked propofol or the
centroid of the three critical amino acids noted above to be
flexible, while maintaining rigidity of the remainder of the
protein. The binding site was created by allowing the most potent
of the etomidate-like derivatives, compound 1n, to dock into its
most favorable pose while relaxing the adjacent amino acid
sidechains, thereby creating an induced-fit binding site which
would be most favorable to ion channel opening given the great
potency and relative rigidity of compound 1n. Docking was performed
using the Flexible Docking algorithm within Discovery Studio 4.0
(Accelrys inc., San Diego, Calif.). Once obtained, further flexible
docking was performed using the aforementioned etomidate-like
derivatives within the series pertaining to compound 1n, the
carbo-1n derivative itself, and finally 12 compounds with at least
80% similarity to carbo-1n. The settings for this calculation
allowed for a 5 angstrom radius about the centroid of the binding
pocket within which amino acid sidechains were allowed to move.
This protocol allows for some receptor flexibility during docking
of flexible ligands. Koska et al. (2008) J Chem InfModel
48:1965-73. The side-chains of specified amino acids are allowed to
move during docking. This allows the receptor to adapt to different
ligands in an induced-fit model. The protocol uses a combination of
components from other protocols to perform the docking, and is
based on methods within CHARMm to sample side-chain and ligand
conformations.
[0225] The Flexible Docking protocol performs the following
steps:
1. Calculate receptor side-chain conformations: Initially, the
protocol creates protein side-chain conformations using the ChiFlex
algorithm. 2. Create ligand conformations: Low energy ligand
conformations are created for the docking process using the
Generate Conformations routine. 3. Perform initial placement of the
ligand conformations: The ligand conformations are docked into the
active site of each receptor side-chain conformation using LibDock.
4. Clustering to remove similar ligand poses: Poses are clustered
regardless of the protein conformation since the protein
conformations are rebuilt during the next step. 5. Refine
side-chains: In the presence of the ligand, the specified receptor
side-chain residues are refined using the ChiRotor algorithm. 6.
Refine docking: A final simulated annealing and energy minimization
of each ligand pose is performed using CDOCKER. CDocker energy
scores as well as CDocker Interaction Energy scores were obtained
for multiple poses of each ligand within the in favorable binding
site.
[0226] The best score for each ligand was then correlated with
GABAaR potentiation EC50 for those compounds in the in series where
such data was available. Such scores were further obtained for
carbo-1n and similar compounds to determine possible predicted
potencies.
[0227] 4. Molecular Modelling of the 11-Beta Hydroxylase Enzyme and
its Interactions with Etomidate, Carboetomidate, 1n and Carbo
1n
[0228] Anesthetics interact with many functional proteins resulting
in a variety of important side effects. In particular, etomidate
has a strong inhibitory effect on a critical enzyme for steroid
biosynthesis, 11-beta hydroxylase (11CYPB). For many patients this
effect can result in catastrophic adrenocortical suppression. Any
complete understanding of these effects is predicated on a more
thorough description of such drug-protein interactions at a
molecular level. While the exact molecular structure of all forms
of 11CYPB remain unknown, significant progress has been made
towards understanding their interactions with anesthetics using
molecular modeling as noted here. A molecular model of 11CYP was
therefore built, and in silico docking analyses of several
important ligands to its binding site were performed. All protein
construction calculations were performed in the Discovery Studio
3.5 software suite (Accelrys, San Diego, Calif.). The amino acid
sequence of the human 11CYPB was obtained from the National Center
for Biotechnology database. A BLAST sequence search was performed
using this sequence to search for sequences of high homology from
those with known three dimensional structures. The four best scored
homologous human sequences were downloaded as 3D coordinates from
the Research Collaboratory for Structural Biology (RCSB) database.
A multiple structure alignment was performed via the SAlign
algorithm to create a sequence profile based upon this structural
alignment. Similarly, a BLAST sequence search was performed using
the human 11CYPB sequence to search for sequences of high homology
from all known amino acid sequences. A multiple sequence alignment
was performed from the resulting 211 sequences identified with good
homology using the ClustalW algorithm. A profile (from the multiple
structure alignment) to profile (from the multiple sequence
alignment) alignment was then performed with ClustalW so as to
align the sequence of the unknown structure with those of the known
structures. The Modeler module was used for assignment of
coordinates for aligned amino acids, the construction of possible
loops, and the initial refinement of amino acid sidechains. Normal
mode analysis was performed using the LAABEN elastic network
algorithm. Partial atomic charges for the heme moiety were computed
using a combined quantum mechanics-molecular mechanics single point
calculation for the heme group region using DMol density functional
theory and a PBE functional, while the remainder of the complex was
treated with a CHARMm molecular mechanics forcefield. Molecular
docking of etomidate and carboetomidate stereoisomers, as well as
the in and carbo in compounds, was performed with the CDocker
algorithm as noted above.
[0229] 5. Behavioral Studies of Newly Identified Lead Compounds in
North American Tadpoles
[0230] Anesthesia is defined as the combination of a lack of
movement to a given stimulus, lack of awareness, amnesia and
analgesia. The surrogate of such is manifest in the tadpole as the
loss of righting reflex (LORR). Early prelimb-bud stage American
bullfrog Rana catesbeiana tadpoles (5 per 50 ml beaker) were placed
in room temperature oxygenated water buffered with 2.5 mM Tris HCl
buffer (pH=7.4) and containing a concentration of test compound
ranging from 0.11 uM-1 mM. Tadpoles were manually tipped every 5
min with a glass rod or stream of water until their righting reflex
response stabilized or 120 minutes elapses. Tadpoles were deemed to
have attained LORR if they failed to right themselves within 5
seconds after being turned over on their back. At the end of each
study, tadpoles were transferred to fresh water to assess whether
the anesthetic action was reversible.
[0231] 6. Electrophysiology in Hippocampal Brain Slices
[0232] The activity of Compound B was assessed on native GABA-A
receptors using well-established electrophysiological techniques in
the CA1 region of the hippocampus obtained from acutely dissected
rodent brains and as discussed in previous work. MacIver (2014)
Anesth Analg 119:558-69.
a. Brain Slice Preparation:
[0233] Experimental protocols were approved by the animal use
committee at Stanford University and adhered to published
guidelines of the National Institutes of Health and the Society for
Neuroscience. Brain slices were prepared from male Sprague-Dawley
rats that had been deeply anesthetized with isoflurane. The brain
was quickly removed and placed in ice-cold artificial cerebrospinal
fluid (ACSF) that was saturated with 95% O.sub.2 and 5% CO.sub.2
(carbogen) to achieve a pH of 7.4. The ACSF was composed of the
following ions dissolved in spectrophotometry grade water (EMD
Chemicals Inc., Billerica, Mass.) and stated in millimolar
concentrations: Na 151.25, Cl 131.5, HCO.sub.3 26, K 2.5, Ca 2, Mg
2, SO.sub.4 2, H.sub.2PO.sub.4 1.25, and glucose 10. Coronal brain
slices were prepared using a vibratome (Model 1500, Technical
Products International Inc., St. Louis, Mo.) and 400-.mu.m-thick
slices were hemisected and placed on cellulose filter papers. They
were stored at a gas (carbogen)-liquid (ACSF) interface in a
holding chamber for at least 1 hour before use.
[0234] Single slices were transferred to a recording chamber and
submerged in room temperature (22.degree. C.) ACSF flowing at a
rate of 3.0 mL/min. ACSF was saturated with carbogen by bubbling
the solution for at least 15 minutes before use. Teflon storage
vessels and tubing were used throughout the perfusion system to
ensure minimal loss of anesthetic agents due to diffusion or
binding.
b. Electrophysiology:
[0235] Evoked field potentials were measured using thin-walled
glass pipettes (1.0 ID, 1.5 OD; Garner Glass Co., Claremont,
Calif.) filled with ACSF. Electrodes were placed in stratum
radiatum to record field excitatory postsynaptic potentials (EPSPs)
or placed in stratum oriens, close to the CA1 cell body layer, to
record population spikes. Bipolar tungsten microelectrodes (10
Mohm; Frederick Haer & Co., Bowdoin, Me.) were placed in
stratum radiatum and used to stimulate Schaffer-collateral fibers
to synaptically drive CA1 neurons. Single- or paired-stimulus
pulses (0.01-0.03 milliseconds duration; unipolar, 10-80 .mu.A at
1.0-8.0 V) were generated from constant current stimulus isolation
units (6D; Grass Instruments, Warwick, R.I.) driven by a Grass
S8800 stimulator. Paired-pulse stimulation was used to measure
anesthetic effects on tonic and fast (first pulse) and slow (second
pulse) inhibitory pathways in the CA1 area neural circuit.
[0236] Recorded signals were conditioned using an Axoclamp 2B
preamplifier (Axon Instruments, Sunnyvale, Calif.) with a bandpass
from DC to 30 kHz and gain of .times.10. Signals were further
amplified (.times.100) and conditioned (DC offset, DC to 30 kHz)
using a differential instrumentation amplifier in single-ended mode
(Model 440; BrownLee Precision, Santa Clara, Calif.). Signals were
digitized at 10 kHz using a National Instruments analog to digital
converter (USB 6009) and Igor Pro software (Wavemetrics Inc., Santa
Clara, Calif.) on a MacBook Pro computer. Responses were measured
and plotted in real time to ensure that stable baselines
(<.+-.2.0% variation) were recorded for at least 20 minutes
before the experiments began. Preparations showing any upward or
downward drift in baseline were not used for experiments.
Drug Solutions:
[0237] Compounds were applied in the ACSF perfusate after at least
15 minutes of equilibration, by bubbling into the ACSF with a
carbogen carrier gas. The compounds were solubilized using 0.5%
dimethyl sulfoxide and vortexed into stock solutions before being
serially diluted into prebubbled (carbogen) ACSF solutions to
achieve final concentrations, just before testing. The compounds
were added as at least a 1/1000 final dilution from concentrated
stock solutions in water. A single concentration of the compound
was tested on each slice preparation to avoid tachyphylaxis or
cross-contamination of drug effects. The entire perfusion system
was cleaned and replaced on a regular basis to avoid
cross-contamination between anesthetics and tested compounds.
c. Data Analysis:
[0238] Time-matched experiments were averaged together using
IgorPro software and graphed as mean.+-.SD of measured responses
versus experimental time (in minutes; sampled 3 times per minute).
Averaged experimental data are displayed as a percentage of control
responses normalized to the size of baseline responses for 20
minutes preceding the start of each experiment.
[0239] Statistical analyses (analysis of variance [ANOVA] with post
Tukey test) comparing non-normalized control, unknown compound
responses and washout were performed using Igor Pro software. In
all cases, "n" refers to individual experiments conducted on
separate slices, usually from different rats.
Results:
[0240] 1. In Silico Model Construction
[0241] The sets of structural alignments from both the SAlign and
3DMA algorithms revealed that there was clear consensus as to the
spatial location of residues relevant to anesthetic effects based
on all templates, except for the intermediate resolution structure
of nAChR (2BG9). That is, when multiple sequence alignments are
performed between all of the structures noted previously along with
the GABAaR and the GlyRa1, the multiple structure alignment agrees
with the positions of homologous residues except for the structure
of 2BG9. These issues with the 2BG9 structure have been noted by
others as well. Hibbs et al. (2011) Nature 474:54-60; Chiara et al.
(2003) Biochemistry 42:13457-67; Ernst et al. (2005) Mol Pharmacol
68:1291-1300. For the anesthetic effect in the human GlyRa1, these
positions are those that are homologous to residues ILE 229, SER
267 and ALA 288. The 2BG9 coordinates had gross discrepancies of
amino acid positions of homologous residues known to alter
anesthetic modulation in several transmembrane domains. The
specific misaligned residues were dependent on the structural
alignment algorithm, but in neither case could the location of all
relevant residues be completely satisfied by the 2BG9 structure. In
particular, using the SAlign algorithm, in the alpha 1 subunit of
the nAChR, it was LEU 257 on TM2, and LEU 279 on TM3 that did not
align with their homologous positions on the remaining templates,
despite multiple sequence alignment to the contrary. Optimizing to
a slightly different structural alignment with the 2BG9 template
using the 3DMA algorithm, it was ILE 220 on TM1 and LEU 257 on TM2
that could not align with their homologous positions on the
remaining templates. This result was the justification for not
using 2BG9 as a template for subsequent modeling, in addition to
the further rationale for using GluCl noted in the Discussion
section.
[0242] Once the GABAaR models were constructed, the preponderance
of secondary structure in the extracellular native ligand binding
domain remained in the beta sheet conformation, while that of the
transmembrane domain remained as tetrameric alpha helical bundles.
This was noted as a consensus in the models derived using the
Modeler method. The models proved extraordinarily similar across
the entire pentameric assembly as well as in the important putative
transmembrane anesthetic binding clefts. As noted in the inventors'
previous work for the GlyRa1, the majority of residues in
homologous proteins that were experimentally labeled as facing
hydrophilic regions also lined the water accessible portions of the
model structures, while those which were experimentally labeled by
lipophilic reagents were often accessible to the lipid membrane
portion of the model. Bertaccini et al. (2010) J Chem Inf Model
50:2248-55. Likewise, experimental data on cysteine crosslinking of
adjacent residues may be partially accounted for with these models
as they are consistent with the ability to form disulfide bonds
between specific intersubunit residue positions on the alpha TM1
subunit and the adjacent beta TM3 subunit. Bali et al. (2012) J
Biol Chem 287:27762-70; Bali et al. (2009) JNeurosci.
29:3083-92.
[0243] The three residues in the mouse GABAaR which were in
homologous positions and notable for modulating anesthetic action
within the transmembrane domain (beta 3 N265, MET286 and alpha
L231), continue to line the intersubunit interface between alpha
and beta subunits after energy optimization (see FIG. 2), as noted
in previous models. Bertaccini et al. (2010) J Chem InfModel
50:2248-55.
[0244] 2. High Throughput Molecular Docking Analyses
[0245] Docking of the propofol derivative series to the region
bound by these residues showed strong linear correlation with
experimentally derived GABAaR potentiation EC50 (see FIG. 3) as
suggested by an R.sup.2 of 0.92.
[0246] CDocker scoring was also validated by the results of the
control compounds with known inactivity at the GABAaR. The CDocker
scores for dicyclohexylphenol, ditert-2,6-butylphenol and
cyclopentylphenol were -14.3 kcal/mol, -13.2 kcal/mol, and -6.0
kcal/mol, respectively. These latter three are all significantly
worse than the lowest potency agonist studied (phenol with a
CDocker score of -16.5 kcal/mol and an EC50 of 920 uM), suggesting
the latter three predicted potencies are well into the millimolar
range and beyond the ranges experimentally tested by Kraswoski et
al. Krasowski et al. (2002) J Med Chem 45:3210-21. The CDocker
binding score was very unfavorable for dicyclopentylphenol (6.5
kcal/mol). The so-called "F6" nonimmobilizer from the Eger group
was docked in both its cis and trans conformations. The CDocker
binding energies were grossly unfavorable for both versions of this
compound (cis=29.1 kcal/mol and trans=28.4) to the putative
anesthetic binding site. This is in stark contrast to the CDocker
energy scores for all of the propofol derivatives studied here that
are agonists and which are clearly in the energetically favorable
negative range. Bertaccini et al. (2013) Anesthesiology
119:1087-95.
[0247] Further docking of the new lead compound series showed
strong correlation of a slightly different docking score, the
CDocker Interaction Energy score (CDIE), with experimentally
derived GABAaR potentiation EC50 (see FIG. 4). This correlation not
only spanned the previously studied propofol-like compounds, but
included several of the etomidate-like derivatives of Biggio et al.
as well as the carbo-1n compound (FIG. 1(B)) in addition to the 12
compounds identified for comparison with carbo-1n (Table 1). In
particular, compound A is roughly an order of magnitude less potent
than compound in which has a known EC50 for GABAaR potentiation of
0.19 uM. Compound B has a predicted potency close to that of
propofol which is further born out by the electrophysiology data
below. As is demonstrated below, the EC50 for GABAaR potentiation
of compound A is approximately 1.5 uM in tadpoles (Table 2).
[0248] 3. Molecular Modelling of the 11 Beta Hydroxylase Enzyme and
its Interactions with Etomidate, Carboetomidate, 1n and
Carbo-1n
[0249] The BLAST derived scores and CLUSTALW profile to profile
alignment demonstrates reasonable sequence similarity between
11CYPB and the modeling templates. The model of the 11CYPB has a
cavity of approximately 810 cubic angstroms in volume and can
readily accommodate a steroid analog. Within the lowest frequency,
highest amplitude natural harmonic motions of this channel, normal
mode analyses suggest that this cavity is located in a region of
reasonable flexibility which could be critical to a
"clamshell-like" opening motion for binding site access. While
etomidate, carboetomidate, in and carbo-1n have docking poses which
show a potentially reversible carbonyl interaction with the heme
Fe, only etomidate and compound in clearly show an imidazole
nitrogen in a position for the undesirable irreversible covalent
interaction with the heme Fe (see FIGS. 5A and 5B). Therefore, it
is predicted that carbo-1n, and the compounds of Table 1, should
not be associated with significant irreversible inhibition of
steroid biosynthesis. Homology modeling produces a model of the
11CYP that reveals a binding site that helps to explain the
differential binding to, and inhibition of, 11CYP for ring
structures containing an imidazole nitrogen and, despite similar
ligand pose within the binding site, the inability for such
irreversible interactions when a single imidazole nitrogen is
changed to a carbon atom.
[0250] 4. Behavioral Studies of Newly Identified Lead Compounds in
North American Tadpoles
[0251] The compounds identified by, and analyzed in, the computer
modeling described above (see Table 1) have been demonstrated to
act as anesthetics in an animal model system. The effects of these
compounds in loss of righting reflex (LORR) assays in tadpoles are
provided in Table 2:
TABLE-US-00002 TABLE 2 Effects of compounds on LORR in tadpoles.
Cpd. EC.sub.50 (uM) for LORR A 1.5 B 0.53 C ~5 D ~20 E ~40 F ~20 G
~3 H >40 J >40 K ~40 M ~20
[0252] Dose-response curves for two of the more potent compounds
are shown in FIG. 6. Panel A=Compound A; Panel B=Compound B. The
effectiveness of each of the compounds as anesthetics is similar to
that of propofol in these assays.
[0253] 5. Electrophysiology in Hippocampal Brain Slices
[0254] The effect of compound B on a hippocampal brain slice
preparation analyzed as described above is shown in FIG. 7. Here
the clear production of the phenomenon known as paired pulse
inhibition can be seen. The occurrence of such is clear evidence of
an effect mediated via the GABAa receptor. This initial effect was
noted at a concentration of 100 uM of test compound compared to a
similar response for propofol in the 10 uM range. This discrepancy
may be explained by differential kinetics and/or metabolism of the
test compound in the hippocampal preparation compared to that of
propofol itself.
DISCUSSION
[0255] For many years, homology modeling of the GABAaR has been
hampered by a limited amount of highly homologous structural
templates. In 1985, the first low resolution cryo-electron
micrograph of the homologous nAChR was released. Brisson et al.
(1985) Nature 315:474-7. Over the next 20 years, this model was
refined to the intermediate resolution of 4 .ANG. and published in
the Research Collaboratory for Structural Biology protein databank
as entry 2BG9. Unwin (2005) J Mol Biol 346:967-89. The model was a
tremendous accomplishment at the time. However, while the 4 .ANG.
cryo-electron micrograph provided great insight into the overall
secondary, tertiary and quaternary structure of this class of
ligand-gated ion channels, the exact atomic delineation of
individual amino acid assignments in three dimensional space was
unclear. Specifically, this cryo-electron micrograph was the
consensus of micrographs over the 4 different subunit subtypes
within the Torpedo nAChR (2 alpha subunits, one beta, one gamma and
one delta). At 4 .ANG. resolution, the globular appearance of
sidechain identities is insufficient to make precise
identifications of individual amino acids.
[0256] Given the recently-released NMR structures of the
transmembrane domains of the alpha 4 and beta 2 nAChR subunits, and
their high homology to the torpedo nAChR, discrepancies in the
amino acid assignments within the subunits of torpedo nAChR (2BG9)
are apparent, making this a much less desirable modeling template
from which to build a GABAaR structure. Cui et al. (2012) Biochim
Biophys Acta 1818:617-26.
[0257] The GABAaR, GluCl, and GLIC templates were initially
considered for homology modeling, based on their homology to the
GABAaR sequence, the availability of a whole pentameric ion channel
construct, and their low root mean square deviation from the NMR
structures of the alpha and beta subunits of the nAChR. The use of
only templates with all 5 subunits, as is the case in all three,
arranged with a pentameric symmetry is considered important for the
analysis of anesthetic interactions, since the location of this
anesthetic binding site within the GABAaR is actually between
specific alpha and beta subunits within the transmembrane domain.
Furthermore, the GluCl structure is thought to be in the open state
of the ion channel pore, a feature believed to be important for
anesthetic binding, since the anesthetic potentiation of the GABAaR
is believed to come from the binding to and stabilization of the
open channel state. Forman et al. (2011) Can J Anaesth 58:191-205.
For comparison, the published structure of GLIC is thought to be
either in the closed or partially open state, and the published
structure of GABAaR beta 3 is thought to be in the desensitized
state. It is also the GluCl structure noted in the 3RIF and 3RHW
templates that actually shows a ligand, ivermectin, bound in the
same transmembrane location as an anesthetic binding site in the
homologous GABAaR. Ivermectin is known to produce a similar
potentiation for the GluCl as anesthetics do for the GABAaR. This
GluCl structure also has the native bound ligand, glutamate, which
further tends the construct towards an open structure.
Additionally, this structure would be similar to the condition of
anesthetic potentiation of the GABAaR in which its native ligand,
gamma amino butyric acid (GABA), must be present. Furthermore,
GluCl is derived from the eukaryote, C. elegans, as opposed to
GLIC, which is derived from the prokaryote, G. violaceus. Since
eukaryotes have cholesterol in their membrane structure and
prokaryotes do not, GluCl may be more representative of the proper
intersubunit helical packing found in higher eukaryotic organisms.
For at least these reasons, the GluCl template formed the basis for
modeling in this disclosure.
[0258] When residues that are known to modulate anesthetic activity
from homologous positions in different LGICs are mapped to the
sequences of known template structures, consensus structural
alignment based on the remaining 5 templates excluding 2BG9
revealed the consistent formation of an intersubunit anesthetic
binding cavity within the transmembrane domain of these
ligand-gated ion channels (see FIG. 2C). This consensus lends
greater confidence to the overall model building process and to
further pursuit of validation analyses. Such analyses have included
the ability to simulate the large-scale motion of the channel that
was performed in previous efforts by the inventors in which an
"iris-like" motion of channel gating was described. Bertaccini et
al. (2010) ACS Chem. Neurosci. 1:552-558; Bertaccini et al. (2008)
J Chem Inf Model 48:855-60; Bertaccini et al. (2005) 7th
International Conference on Basic and Systematic Mechanisms of
Anesthesia. Nara, Japan, Elsevier, pp 160-163. Further validation
of the process also came in the form of channel responses to ligand
binding via long term molecular dynamics simulations. This has been
accomplished with molecular dynamics simulations in previous models
of the GlyRa1 in the presence and absence of ethanol for 1
microsecond periods. Murail et al. (2011) Biophys J 100:1642-50.
However, actual channel gating occurs on timescales that are orders
of magnitude larger and will require computational resources not
currently available. Additional validation is now presented in the
instant disclosure via the correlation of relative binding energy
scores with experimentally derived measures of GABAaR
potentiation.
[0259] The location of anesthetic binding sites within the LGICs
continues to be a topic of debate but is not critical for the
practice of the instant invention. One of the proposed sites has
been examined in this disclosure. There is evidence that
anesthetics bind to sites within the transmembrane subunits of
homologous proteins, specifically in GLIC and the Erwinia
chrysanthemi ion channel (ELIC). In former models of various LGICs
based on older templates, certain constructs were presented which
postulated such an intrasubunit binding site for anesthetics within
the glycine receptor as well. Bertaccini et al. (2005) J Chem
InfModel 45:128-35. However, newer more homologous templates allow
the construction of more robust models in which there is a
convergence of residues relevant to anesthetic modulation on a
common intersubunit binding site. As suggested in a recent
publication from the inventors' laboratory (Murail et al. (2012)
PLoS Comput Biol 8:e1002710), a key site for anesthetic and alcohol
action may be between the transmembrane subunits. An even more
interesting occurrence has been shown in the crystal structure of
Erwinia chrysanthemi ion channel (ELIC) with the anesthetic
bromoform, in which both potentiation and inhibition have been
noted by binding of the anesthetic to an intersubunit transmembrane
cleft (Spurny et al. (2013) J Biol Chem 288:8355-64) in addition to
effects within the pore and extracellular domains. Furthermore, the
extracellular domain within this class of ion channels involves its
own set of inter- and intrasubunit clefts. Pan et al. have
demonstrated that the intravenous general anesthetic, ketamine,
binds at an intersubunit site and causes inhibition of the channel
in the extracellular or native ligand binding domain of the
protein. Pan et al. (2012) Structure 20:1463-9. However, the
instant work is to merely examine one of these putative binding
sites which has been extensively studied in the inventors' previous
modeling studies and in the experimental work of other groups. This
binding site has clearly been shown to be both necessary and
sufficient to mediate anesthetic effects in several circumstances.
Bertaccini et al. (2010) J Chem Inf Model 50:2248-55; Murail et al.
(2012) PLoS Comput Biol 8:e1002710; Jenkins et al. (2001) J
Neurosci 21:RC136; Mihic et al. (1997) Nature 389:385-9.
[0260] Once a binding site has been identified in the computer
model, further validation and utility of the model must come from
predictions of anesthetic affinity and possible activity in
compounds that have heretofore not been known to have anesthetic
potency. This goal would be accomplished through the application of
a wide variety of molecular docking and scoring schemes which allow
individual compounds to be docked to a designated anesthetic
binding site within the protein in question, as has been described
recently. Liu et al. (2012) Anesth Analg 114:947-55. Any such
endeavor is dependent on the ability to at least predict the orders
of potency within a series of similar anesthetic ligands from a
qualitative standpoint and, when feasible, predict a quantitative
measure as well. The energetic parameter which should ultimately
correlate with such potency is the free energy of ligand binding.
However, total free energy is dependent on both enthalpy and
entropy. Accounting for the binding entropy changes can be very
difficult using computational methods. Ligands which vary markedly
in size and shape could have very different entropic contributions
to binding that are poorly accounted for by anything other than
very complex and computationally expensive free energy perturbation
calculations that are impractical for high throughput screens.
However, within a reasonably similar congeneric series of ligands,
as utilized here, such an entropic contribution can be assumed to
be similar amongst members, with the enthalpic contribution of
binding dominating the relative interactions. It is this enthalpic
contribution that is most closely related to the docking scores
presented here. With this, the instant model of an anesthetic
binding pocket has characteristics that allow reasonable
correlation of ligand enthalpic docking scores with actual
experimentally derived measures of GABAaR potentiation for the set
of propofol and etomidate-like derivatives studied.
[0261] All patents, patent publications, and other published
references mentioned herein are hereby incorporated by reference in
their entireties as if each had been individually and specifically
incorporated by reference herein.
[0262] While specific examples have been provided, the above
description is illustrative and not restrictive. Any one or more of
the features of the previously described embodiments can be
combined in any manner with one or more features of any other
embodiments in the present invention. Furthermore, many variations
of the invention will become apparent to those skilled in the art
upon review of the specification. The scope of the invention
should, therefore, be determined by reference to the appended
claims, along with their full scope of equivalents.
* * * * *